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Abstract: The first example of Lewis acid catalyzed enantioselective 
ring-opening desymmetrization of donor-acceptor meso-
diaminocyclopropanes is reported herein. A copper(II)-catalyzed 
Friedel-Crafts alkylation of indoles and a pyrrole with an 
unprecedented meso-diaminocyclopropane delivered 
enantioenriched diastereomerically pure urea products, which are 
structurally related to natural and synthetic bioactive compounds. 
The development of a new ligand through the investigation of an 
underexplored subclass of BOX ligands was essential for obtaining 
high enantiomeric ratios. 
Donor-acceptor cyclopropanes are versatile building blocks in 
organic synthesis.[1] Enantiomerically enriched derivatives can 
be obtained by performing asymmetric transformations. Donor-
acceptor cyclopropanes are often themselves chiral, leading to 
two possible scenarios: kinetic resolution and DYKAT (dynamic 
kinetic asymmetric transformation).[2] Our group applied a 
DYKAT for the first time to donor-acceptor aminocyclopropanes 
(Scheme 1, A).[2i] However, a major drawback of DYKAT 
processes lies in their complex reaction mechanism, requiring 
both efficient facial selection and control over racemization. In 
contrast, the desymmetrization of achiral meso substrates leads 
often to a more straightforward development of enantioselective 
transformations.[3] We therefore designed a novel meso-
diaminocyclopropane 2 (Scheme 1, B). Up to now, only 
nucleophile, base and amine (via iminium-enamine) catalysts 
have been reported for the desymmetrization of donor-acceptor 
meso- cyclopropanes (Scheme 1, C).[4]  
Herein, we present the first example of enantioselective 
desymmetrization of nitrogen-substituted cyclopropanes for the 
Friedel-Crafts alkylation of indoles using a copper catalyst 
bearing an unprecedented BOX (bisoxazoline) ligand (Scheme 1, 
B). The methodology delivered enantioenriched urea derivatives 
as products, which are highly important core structures in natural 
and bioactive compounds such as Tulongicin A (3),[5a] Biotin 
(4)[5b] or (-)-Agelastatin A (5)[5c-d](Figure 1).[5] 
 
Scheme 1. DYKAT of aminocyclopropanes (A). This work: enantioselective 
desymmetrization of donor-acceptor meso-diaminocyclopropanes (B). State-
of-the-art in enantioselective desymmetrization of cyclopropanes (C). Succ = 
succinyl, Piv = pivaloyl. 
 
Figure 1. Occurrence of urea derivatives in synthetic and natural bioactive 
compounds. 
The investigation of the proposed transformation required first 
an adequate donor-acceptor meso-diaminocyclopropane. Based 
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on our previous work,[2i] an imide urea functionality as the donor, 
and a bis-ester as the acceptor were chosen (cyclopropane 2). 
The Friedel-Crafts alkylation with indoles was examined first.[2e,8] 
We focused our effort on copper-bisoxazoline (BOX) complexes 
as catalysts.[2i] Both the electron-withdrawing group on the urea 
and the N-substituent on the indole showed a strong effect on 
enantioselectivity (see SI for details). The best compromise 
between enantiomeric ratio (er) and solubility was achieved by 
using a pivaloyl group on urea 2 and tert-butyldimethysilyl (TBS) 
protected indole 6a (Scheme 2). Copper(II) was identified as the 
best metal, hexafluoroantimonate(V) as the best counterion, and 
BOX ligands such as 8 as a promising class of ligands. In 
toluene as solvent, the desired product could be obtained in 
74% yield and 18:82 er as a single diastereoisomer. 
 
Scheme 2. Lead result for the enantioselective Friedel-Crafts alkylation of 
indole 6a with cyclopropane 2. Reaction conditions: 0.05 mmol 2, 0.06 mmol 
3a, 0.05 M in Toluene, -20 °C, 48 h. TBS = tert-butyldimethylsilyl. 
To improve further the er, we investigated ligand modification at 
the  position to the nitrogen atom. We were particularly 
interested in a subclass of BOX ligands bearing bulky 
diarylmethanol groups instead of the tert-butyls (Scheme 3, A).[9] 
The aryl groups can be installed by Grignard addition to the 
ester precursor 9, which can be easily synthesized in two steps 
from serine ester.[10] Up to now, only the phenyl derivative (10a) 
has been reported.[9] It was used by Reiser and coworkers for 
the enantioselective 1,2- and 1,4-addition of organozincs to 
carbonyl compounds. The use of 10a in the Friedel-Crafts 
reaction afforded a significant increase in er (Scheme 3, B). 
When the alcohol was protected as a benzyl group (11a), the 
opposite enantiomer was obtained in lower er. Subsequently, 
the substitution pattern on the aryl groups was investigated. 
Substitution in the ortho position could not be accessed 
synthetically, whereas a methyl group in meta gave a better er 
(ligand 10b). Ligand 10c with a methyl in para position led to a 
decrease of er. The er could be further improved to 89.5:10.5 by 
adding a second methyl group in meta position (ligand 10d). Any 
further change in the meta positions, either by increased steric 
bulk (ligand 10e) or by introducing electron-donating or 
withdrawing substituents (ligands 10f and 10g) only resulted in 
lower er. Replacing the benzene by a naphthalene ring was also 
not successful (ligand 10h). Using 1.5 equivalents of 
cyclopropane 2 compared to indole 6a, lowering the temperature 
to -50 °C, and diluting to 0.025 M finally afforded the desired 
product 7a in 80% yield and 94.2:5.8 er on scope scale (Scheme 
4). 
We then investigated the scope of the reaction (Scheme 4). 
Indoles bearing both electron-withdrawing groups such as 
halides, esters, and trifluoromethyl (products 7b to 7i) and 
electron-donating groups such as methyl and methoxy (products 
7j to 7l) delivered products in 64-84% yield and 90.7:9.3 to 
96.7:3.3 er.[11] A phenyl substituent was also well-tolerated 
(product 7m), as well as a fused cyclopentyl ring (product 7n). 
The reaction could also be extended to pyrroles without 
reoptimization: TIPS-protected pyrrole 6o gave product 7o in 
good yield and promising er.[12] 
 
Scheme 3. Ligand synthesis (A). Reaction conditions: a) ArMgBr (6 equiv), 
0.067 M in THF, -78 °C to rt, 24 h. b) NaH (2.4 equiv), BnBr (2.4 equiv), 0.5 M 
in DMF, 0 °C to rt, 16 h. Ligand screening for the alkylation of 6a with 2 (B). 
Reaction conditions as in Scheme 2 but at rt for 16 h. >20:1 dr was observed 
in all cases. The yields and er's of 7a are reported below each ligand. Bn = 
benzyl. 
 
Scheme 4. Scope of the reaction. Reaction conditions: 0.15 mmol 2, 0.1 mmol 
6, 0.025 M in Toluene, -50 °C for all the entries except 7g and 7h (-40 °C) and 
7i and 7o (-30 °C). All compounds were obtained with dr > 20:1. TIPS = 
triisopropylsilyl. 
A single pivaloyl group of the product could be selectively 
deprotected using hydrazine to deliver 12 in excellent yield 
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without purification (Scheme 5). Basic hydrolysis led then to 
cleavage of the remaining pivaloyl group, the two methyl esters 
as well as the silyl protecting group, revealing the free urea. 
Subsequent decarboxylation/methylation of the dicarboxylic acid 
afforded 13 in 56% yield without erosion of enantiopurity. 
 
Scheme 5. Product derivatizations. Reaction conditions: a) N2H4 (aq) 80% wt 
(1.5 equiv), rt. b) i. 0.5 M LiOH(aq) (8 equiv), rt; ii. MeOH, 80 °C; iii. TMSCHN2 
(10 equiv), 0 °C. 56% yield over three steps. 
X-ray analysis of 7d showed that the configuration was 3R,4R 
(see Figure S1 in SI).[13] The trans relative configuration supports 
a SN2-like mechanism for the ring-opening of the cyclopropane. 
Based on the obtained absolute configuration, a highly 
speculative stereochemical model can be proposed (Figure 2). 
We assume that the copper complex adopts a distorted square 
planar geometry due to hydrogen bonds between the hydroxy 
groups and the esters of the cyclopropane, forcing them in the 
more hindered quadrants and further activating them.[14,15] 
Indeed, rate acceleration was observed when employing ligands 
bearing a free hydroxy group.[16] In the resulting rigidified 
structure, we propose a relay of stereoinduction from the aryl 
groups to the pivaloyls, the latter orienting their smallest 
substituent (carbonyl) towards the bulky aryl groups. This results 
in an opposite orientation of the two carbonyl groups compared 
to the urea carbonyl, blocking selectively one of the electrophilic 
carbon of the cyclopropane with a tert-butyl group.  
 
Figure 2. Speculative stereochemical model. 
In summary, we have developed the first Lewis acid 
catalyzed enantioselective ring-opening desymmetrization of 
donor-acceptor cyclopropanes. The transformation displayed 
high enantioselectivity and complete diastereoselectivity, 
together with a broad scope of indoles as well as a pyrrole, 
delivering urea derivatives that are important scaffolds in natural 
and synthetic bioactive compounds. The use and further 
modification of an underexploited class of BOX ligands easily 
obtained in two steps from serine ester was essential to achieve 
high enantioselectivity. We believe that these ligands will be 
useful also in other new asymmetric transformations. 
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1. General methods 
All reactions were carried out in oven- or flame- dried glassware under an atmosphere of nitrogen, unless 
stated otherwise. For quantitative flash chromatography, distilled technical grade solvents were used. 
THF, Et2O, toluene, hexane and CH2Cl2 were dried by passage over activated alumina under nitrogen 
atmosphere (H2O content < 7 ppm, Karl-Fischer titration). All chemicals were purchased and used as 
received unless stated otherwise. Chromatographic purification was performed as flash chromatography 
using Macherey-Nagel silica 40-63, 60 Å, using the solvents indicated as eluent with 0.1-0.5 bar pressure. 
TLC was performed on Merck silica gel 60 F254 TLC plastic or aluminium plates and visualized with 
UV light, permanganate CAN or p-anisaldehyde stains. Melting points were measured on a calibrated 
Büchi B-540 melting point apparatus using open glass capillaries. 1H-NMR spectra were recorded at 
room temperature on a Brucker DPX-400 400 MHz spectrometer in CDCl3, DMSO-d6 or CD3OD, all 
signals are reported in ppm with the internal chloroform signal at 7.26 ppm, the internal DMSO signal 
at 2.50 ppm and the internal methanol signal at 3.31 ppm as standard. The data is being reported as (s = 
singlet, d = doublet, t = triplet, q = quadruplet, p = quintet, m = multiplet or unresolved, br = broad 
signal, app = apparent, coupling constant(s) in Hz, integration, interpretation). 13C-NMR spectra were 
recorded with 1H-decoupling on a Brucker DPX-400 100 MHz spectrometer in CDCl3 or CD3OD, all 
signals are reported in ppm with the internal chloroform signal at 77.0 ppm or CD3OD signal at 49.0 
ppm as standard. Infrared spectra were recorded on a JASCO FT-IR B4100 or a Bruker Alpha-P 
spectrophotometer with an ATR device and a ZnSe prism and are reported as cm-1 (w = weak, m = 
medium, s = strong). High resolution mass spectrometric measurements were performed by the mass 
spectrometry service of ISIC at the EPFL on a MICROMASS (ESI) Q-TOF Ultima API. HPLC 
measurements were done on a Agilent 1260 Infinity autosampler using a CHIRALPAK IA, IB, IC or IF 
column from DAICEL Chemical. Optical rotations were measured on a polarimeter using a 10 cm cell 
with a Na 589 nm filter. The specific solvents and concentrations (in g/100 mL) are indicated. 
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2. Preparation of the starting materials 
2.1 Synthesis of the cyclopropanes 
Dimethyl 2-diazomalonate (14) 
 
In a flame dried flask under N2 atmosphere, 4-acetamidobenzenesulfonyl azide (6.82 g, 28.4 mmol, 1.5 
equiv) was dissolved in acetonitrile (80 mL) and triethylamine (6.3 mL, 45 mmol, 2.4 equiv) and 
dimethyl malonate (2.2 mL, 19 mmol, 1 equiv) were added. The reaction mixture was stirred at room 
temperature for 24 hours. The solvent was evaporated and the crude product was filtered on cotton with 
acetonitrile (30 mL). The crude mixture was concentrated under reduced pressure and filtered on cotton 
one more time with DCM (30 mL) and finally purified by column chromatography (deactivated SiO2, 
eluent pentane:ethyl acetate 9:1 + 1% of triethylamine) to give dimethyl 2-diazomalonate (14) (2.67 g, 
16.9 mmol, 94% yield) as a slightly yellow oil (solid at 4 °C). 
1H NMR (400 MHz, CDCl3) δ 3.83 (s, 6H, CH3). 
Data match the literature report.[1] 
1H-imidazol-2(3H)-one (15) 
 
Following a reported procedure,[2] in a flame dried flask under N2 atmosphere, hydantoin (10.0 g, 100 
mmol, 1 equiv) was suspended in 100 mL of dry tetrahydrofuran. The suspension was cooled to 0 °C 
with an ice/water bath. A 1.2 molar solution of DIBAL in toluene (221 mL, 265 mmol, 2.65 equiv) was 
added dropwise over 30 minutes, and the solution was stirred for 2 hours at 0 °C. 700 mL of a solution 
of 9:1 methanol/water was added carefully, and the reaction was heated at 100 °C for 18 hours. After 
cooling to room temperature, the reaction was filtered on celite, eluting with 500 mL of methanol, and 
evaporated to dryness to give 1H-imidazol-2(3H)-one (15) (7.00 g, 83.0 mmol, 83% yield) as an off-
white solid. 
1H NMR (400 MHz, DMSO-d6) δ 9.75 (s, 2H, NH), 6.24 (s, 2H, CH). 
Data match the literature report.[2] 
1,1'-(2-Oxo-1H-imidazole-1,3(2H)-diyl)diethanone (16) 
                                                          
1 Racine, S.; Hegedus, B.; Scopelliti, R.; Waser, J., Chem. Eur. J. 2016, 22, 11997-12001. 
2 Groaz, I.; Banti, D.; North, M., Tetrahedron 2008, 64, 204-218. 
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Following a reported procedure,[2] 1H-imidazol-2(3H)-one (15) (300 mg, 3.57 mmol, 1 equiv) was 
stirred in acetic anhydride (1.94 mL, 20.5 mmol, 5.8 equiv) at reflux for 90 minutes. The reaction was 
cooled down to room temperature and concentrated to dryness. The residue was washed with ethyl 
acetate to afford 1,1'-(2-oxo-1H-imidazole-1,3(2H)-diyl)diethanone (16) (360 mg, 2.14 mmol, 60% 
yield) as a white solid. 
 
1H NMR (400 MHz, CDCl3) δ 7.08 (s, 2H, CH), 2.65 (s, 6H, CH3). 
Data match the literature report.[3] 
(2-Oxo-1H-imidazole-1,3(2H)-diyl)bis(phenylmethanone) (17) 
 
Following a reported procedure,[3] in a flame dried flask under N2 atmosphere, 1H-imidazol-2(3H)-one 
(15) (1.18 g, 6.16 mmol, 1 equiv) was added, followed by 42.4 mL of dry dichloromethane, and the 
suspension was cooled to 0 °C. Then, DMAP (0.171 g, 1.40 mmol, 0.1 equiv) was added, followed by 
a solution of benzoyl chloride (3.25 mL, 28.0 mmol, 2 equiv) in dry dichloromethane (5.6 mL) dropwise. 
Finally, triethylamine (3.90 mL, 2.83 mmol, 2 equiv) was added dropwise. The reaction mixture was 
stirred at 0 °C, letting ice melt during 24 hours. 50 mL of dichloromethane were added, and the organic 
layer was washed with water (60 mL). The aqueous layer was separated and extracted with 
dichloromethane (40 mL). The combined organic layers were washed with brine (50 mL), dried over 
Na2SO4, filtered and evaporated. The residue was purified by column chromatography (SiO2, eluent 
pentane:ethyl acetate 85:15 to 0:100), to afford (2-oxo-1H-imidazole-1,3(2H)-
diyl)bis(phenylmethanone) (17) (1.80 g, 6.16 mmol, 44% yield) as a white solid. 
 
Rf: (SiO2, pentane:ethyl acetate 9:1) 0.21; 
1H NMR (400 MHz, CDCl3) δ 7.81 - 7.71 (m, 4H, ArH), 7.58 - 7.53 (m, 2H, ArH), 7.43 (t, J = 7.7 Hz, 
4H, ArH), 7.11 (s, 2H, CH). 
Data match the literature report.[3] 
1,1'-(2-Oxo-1H-imidazole-1,3(2H)-diyl)bis(2,2-dimethylpropan-1-one) (18) 
 
Following a modified procedure,[3] in a flame dried flask under N2 atmosphere, 1H-imidazol-2(3H)-one 
(15) (3.00 g, 35.7 mmol, 1 equiv) was added, followed by 100 mL of dry dichloromethane, and the 
suspension was cooled to 0 °C. Then, DMAP (0.436 g, 3.57 mmol, 0.1 equiv) was added, followed by 
a solution of pivaloyl chloride (9.66 mL, 78.0 mmol, 2.2 equiv) in dry dichloromethane (35 mL) 
dropwise. Finally, triethylamine (10.4 mL, 74.9 mmol, 2.1 equiv) was added dropwise. The reaction 
                                                          
3 Han, S.; Zard, S. Z., Org. Lett. 2014, 16, 5386-5389. 
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mixture was stirred at 0 °C, letting ice melt during 24 hours. 50 mL of dichloromethane were added, and 
the organic layer was washed with water (60 mL). The aqueous layer was separated and extracted with 
dichloromethane (40 mL). The combined organic layers were washed with brine (50 mL), dried over 
Na2SO4, filtered and evaporated. The residue was purified by column chromatography (SiO2, eluent 
pentane:diethylether 9:1), to afford 1,1'-(2-Oxo-1H-imidazole-1,3(2H)-diyl)bis(2,2-dimethylpropan-1-
one) (18) (6.93 g, 27.5 mmol, 77% yield) as a white solid. 
 
Rf: (SiO2, pentane:diethylether 94:6) 0.2; 
Mp: 76-78 °C; 
1H NMR (400 MHz, CDCl3) δ 7.06 (s, 2H, CH), 1.44 (s, 18H, C(CH3)3); 
13C NMR (101 MHz, CDCl3) δ 176.5, 149.9, 111.9, 41.6, 25.8; 
IR (film) ?̃? 2974 (w), 1705 (s), 1483 (w), 1299 (w), 1194 (w), 911 (m), 738 (s); 
HRMS (ESI) calcd. for C13H20N2NaO3+ [M+Na]+ 275.1366; found 275.1120. 
Dimethyl 2,4-diacetyl-3-oxo-2,4-diazabicyclo[3.1.0]hexane-6,6-dicarboxylate (19) 
 
Following a modified procedure,[1] in a glovebox, rhodium(II) acetate dimer (32.0 mg, 71.0 µmol, 0.05 
equiv) was added in a flame dried flask. The flask was closed with a septum, put under N2 atmosphere, 
and cooled down to 0 °C. A solution of 1,1'-(2-oxo-1H-imidazole-1,3(2H)-diyl)diethanone (16) (240 
mg, 1.43 mmol, 1 equiv) in dry dichloromethane (3.5 mL) was added in the flask. After 5 minutes, a 
solution of dimethyl 2-diazomalonate (14) (271 mg, 1.71 mmol, 1.2 equiv) in dry dichloromethane (3.5 
mL) was added dropwise. The reaction mixture was stirred at 0 °C, letting ice melt during 15 hours. The 
solvent was then evaporated at the rotavap. The residue was purified by column chromatography (SiO2, 
eluent pentane:ethyl acetate 65:35), to afford dimethyl 2,4-diacetyl-3-oxo-2,4-
diazabicyclo[3.1.0]hexane-6,6-dicarboxylate (19) (210 mg, 0.704 mmol, 49% yield) as a white solid, 
which was stored at -20 °C in the freezer under N2 atmosphere. 
 
Rf: (SiO2, pentane: ethyl acetate 7:3) 0.17; 
Mp: 119-123 °C; 
1H NMR (400 MHz, CDCl3) δ 4.55 (s, 2H, NCH), 3.78 (s, 3H, CO2CH3), 3.71 (s, 3H, CO2CH3), 2.52 
(s, 6H, CH3); 
13C NMR (101 MHz, CDCl3) δ 170.0, 165.8, 163.2, 150.8, 53.4, 53.2, 38.4, 33.7, 23.7; 
IR (film) ?̃? 1769 (m), 1721 (s), 1440 (w), 1375 (w), 1339 (s), 1273 (m), 1231 (s), 1166 (w), 1088 (s), 
981 (w), 915 (w); 
HRMS (ESI) calcd. for C12H15N2O7+ [M+H]+ 299.0874; found 299.0882. 
Dimethyl 2,4-dibenzoyl-3-oxo-2,4-diazabicyclo[3.1.0]hexane-6,6-dicarboxylate (20) 
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Following a modified procedure,[1] in a glovebox, rhodium(II) acetate dimer (113 mg, 257 µmol, 0.05 
equiv) was added in a flame dried flask. The flask was closed with a septum, put under N2 atmosphere, 
and cooled down to 0 °C. A solution of (2-oxo-1H-imidazole-1,3(2H)-diyl)bis(phenylmethanone) (17) 
(1.50 g, 5.13 mmol, 1 equiv) in dry dichloromethane (15 mL) was added in the flask. After 5 minutes, a 
solution of dimethyl 2-diazomalonate (14) (974 mg, 6.16 mmol, 1.2 equiv) in dry dichloromethane (15 
mL) was added dropwise. The reaction mixture was stirred at 0 °C, letting ice melt during 14 hours. The 
solvent was then evaporated at the rotavap. The residue was purified by column chromatography (SiO2, 
eluent toluene:ethyl acetate 10:1), to afford dimethyl 2,4-dibenzoyl-3-oxo-2,4-
diazabicyclo[3.1.0]hexane-6,6-dicarboxylate (20) (1.40 g, 3.31 mmol, 65% yield) as a white solid, 
stored at -20 °C in the freezer under N2 atmosphere. 
 
Rf: (SiO2, toluene:ethyl acetate 8:2) 0.62; 
Mp: 119-123 °C; 
1H NMR (400 MHz, CDCl3) δ 7.64 – 7.58 (m, 4H, ArH), 7.52 – 7.47 (m, 2H, ArH), 7.40 – 7.35 (m, 4H, 
ArH), 4.76 (s, 2H, NCH), 3.85 (s, 3H, CO2CH3), 3.79 (s, 3H, CO2CH3); 
13C NMR (101 MHz, CDCl3) δ 169.1, 165.9, 163.5, 149.3, 132.5, 132.4, 129.0, 127.9, 53.4, 53.1, 40.0, 
34.3; 
IR (film) ?̃? 2952 (w), 1787 (m), 1733 (s), 1691 (s), 1440 (w), 1333 (s), 1279 (s), 1225 (s), 1160 (s), 
1082 (w), 915 (w), 825 (w); 
HRMS (ESI) calcd. for C22H18N2NaO7+ [M+Na]+ 445.1006; found 445.1008. 
Dimethyl 3-oxo-2,4-dipivaloyl-2,4-diazabicyclo[3.1.0]hexane-6,6-dicarboxylate (2) 
 
Following a modified procedure,[1] in a glovebox, rhodium(II) acetate dimer (438 mg, 991 µmol, 0.05 
equiv) was added in a flame dried flask. The flask was closed with a septum, put under N2 atmosphere, 
and cooled down to 0 °C. A solution of 1,1'-(2-oxo-1H-imidazole-1,3(2H)-diyl)bis(2,2-dimethylpropan-
1-one) (18) (5.00 g, 19.8 mmol, 1 equiv) in dry dichloromethane (60 mL) was added in the flask. After 
5 minutes, a solution of dimethyl 2-diazomalonate (14) (3.45 g, 21.8 mmol, 1.1 equiv) in dry 
dichloromethane (40 mL) was added dropwise. The reaction mixture was stirred at 0 °C, letting ice melt 
during 15 hours. The solvent was then evaporated at the rotavap. The residue was purified by column 
chromatography (SiO2, eluent pentane:ethyl acetate 9:1), to afford dimethyl 3-oxo-2,4-dipivaloyl-2,4-
diazabicyclo[3.1.0]hexane-6,6-dicarboxylate (2) (3.40 g, 8.89 mmol, 45% yield) as a white solid, stored 
at -20 °C in the freezer under N2 atmosphere. 
 
Rf: (SiO2, pentane:ethyl acetate 7:3) 0.67; 
Mp: 100-102 °C; 
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1H NMR (400 MHz, CDCl3) δ 4.50 (s, 2H, NCH), 3.76 (s, 3H, CO2CH3), 3.67 (s, 3H, CO2CH3), 1.37 
(s, 18H, C(CH3)3);  
13C NMR (101 MHz, CDCl3) δ 178.4, 166.4, 163.2, 148.4, 53.1, 52.8, 41.4, 40.8, 33.9, 26.1; 
IR (film) ?̃?1742 (s), 1690 (s), 1627 (w), 1371 (s), 1287 (s), 1230 (s), 1204 (m), 1167 (w), 1125 (w), 900 
(w), 869 (w); 
HRMS (ESI) calcd. for C18H27N2O7+ [M+H]+ 383.1813; found 383.1825. 
2.2 Synthesis of the protected indoles 
1-(Tert-butyldimethylsilyl)-1H-indole (6a) 
 
Following a modified procedure[4], a solution of 1H-indole (21) (0.586 g, 5.00 mmol, 1 equiv) in THF 
(4 mL) was added dropwise to a suspension of NaH (60% suspension in mineral oil, 0.600 g, 15.0 mmol, 
3 equiv) in THF (5 mL) under N2 atmosphere at 0 °C. The mixture was allowed to warm to room 
temperature with stirring over 45 minutes to give a near homogenous solution. After re-cooling to 0 °C, 
tert-butylchlorodimethylsilane (0.904 g, 6.00 mmol, 1.2 equiv) was added as a solution in THF (3 mL). 
The mixture was allowed to warm to room temperature and stirred for 12 hours. The mixture was diluted 
with Et2O (25 mL) and water (10 mL). The organic layer was washed with brine (10 mL), dried over 
MgSO4, concentrated under reduced pressure. Purification by flash column chromatography (SiO2, 
eluent pentane:ethyl acetate 40:1) afforded 1-(Tert-butyldimethylsilyl)-1H-indole (6a) (1.08 g, 4.67 
mmol, 93% yield) as white solid. 
 
Rf: (SiO2, pentane) 0.42; 
1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 7.9 Hz, 1H, ArH), 7.52 (d, J = 8.2 Hz, 1H, ArH), 7.19 (d, J 
= 3.2 Hz, 1H, ArH), 7.18 – 7.08 (m, 2H, ArH), 6.62 (d, J = 3.1 Hz, 1H, ArH), 0.94 (s, 9H, SiC(CH3)3), 
0.61 (s, 6H, 2 x SiCH3). 
Data match the literature report.[4] 
1-(Tert-butyldimethylsilyl)-5-chloro-1H-indole (6b) 
 
Following a modified procedure,[4] a solution of the 5-chloro-1H-indole (22) (0.240 g, 1.58 mmol, 1 
equiv) in THF (2 mL) was added dropwise to a suspension of NaH (60% suspension in mineral oil, 
0.190 g, 4.75 mmol, 3 equiv) in THF (3 mL) under N2 atmosphere at 0 °C. The mixture was allowed to 
warm to room temperature with stirring over 45 minutes to give a near homogenous solution. After re-
cooling to 0 °C, tert-butylchlorodimethylsilane (0.380 g, 2.53 mmol, 1.6 equiv) was added as a solution 
in THF (2 mL). The mixture was allowed to warm to room temperature and stirred for 12 hours. The 
mixture was diluted with Et2O (25 mL) and water (10 mL). The organic layer was washed with brine 
(10 mL), dried over MgSO4, concentrated under reduced pressure. Purification by flash column 
                                                          
4 Caramenti, P.; Nicolai, S.; Waser, J., Chem. Eur. J. 2017, 23, 14702-14706. 
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chromatography (SiO2, eluent pentane) afforded 1-(Tert-butyldimethylsilyl)-5-chloro-1H-indole (6b) 
(0.375 g, 1.41 mmol, 89% yield) as pale yellow oil. 
Rf: (SiO2, pentane) 0.38; 
1H NMR (400 MHz, CDCl3) δ 7.58 (dd, J = 2.2, 0.5 Hz, 1H, ArH), 7.40 (d, J = 8.8 Hz, 1H, ArH), 7.19 
(d, J = 3.2 Hz, 1H, ArH), 7.09 (dd, J = 8.8, 2.2 Hz, 1H, ArH), 6.55 (dd, J = 3.2, 0.9 Hz, 1H, ArH), 0.91 
(s, 9H, SiC(CH3)3), 0.60 (s, 6H, 2 x SiCH3); 
13C NMR (101 MHz, CDCl3) δ 139.3, 132.5, 132.4, 125.5, 121.6, 120.0, 114.7, 104.4, 26.2, 19.5, -4.0; 
IR (film) ?̃? 2959 (m), 2928 (m), 2860 (m), 1510 (w), 1448 (s), 1288 (m), 1257 (m), 1201 (w), 1152 (s), 
986 (m), 838 (s), 794 (s); 
HRMS (ESI) calcd. for C14H21ClNSi+ [M+H]+ 266.1126; found 266.1126. 
1-(Tert-butyldimethylsilyl)-6-chloro-1H-indole (6c) 
 
Following a modified procedure,[4] a solution of the 6-chloro-1H-indole (23) (0.30 g, 2.0 mmol, 1.0 
equiv) in THF (2 mL) was added dropwise to a suspension of NaH (60% suspension in mineral oil, 0.24 
g, 6.0 mmol, 3.0 equiv) in THF (3 mL) under N2 atmosphere at 0 °C. The mixture was allowed to warm 
to room temperature with stirring over 45 minutes to give a near homogenous solution. After re-cooling 
to 0°C, tert-butylchlorodimethylsilane (0.45 g, 3.0 mmol, 1.5 equiv) was added as a solution in THF 
(1.5 mL). The mixture was allowed to warm to room temperature and stirred for 12 hours. The mixture 
was diluted with Et2O (25 mL) and water (10 mL). The organic layer was washed with brine (10 mL), 
dried over MgSO4, concentrated under reduced pressure. Purification by flash column chromatography 
(SiO2, eluent pentane: ethyl acetate 20:1) afforded 1-(Tert-butyldimethylsilyl)-6-chloro-1H-indole (6c) 
(0.46 g, 1.7 mmol, 87% yield) as yellow oil. 
 
Rf: (SiO2, pentane) 0.41; 
Mp: 80.3-80.8 °C; 
1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 8.4 Hz, 1H, ArH), 7.47 (s, 1H, ArH), 7.16 (d, J = 3.2 Hz, 
1H, ArH), 7.08 (d, J = 8.3 Hz, 1H, ArH), 6.58 (d, J = 3.1 Hz, 1H, ArH), 0.93 (s, 9H, SiC(CH3)3), 0.60 
(s, 6H, 2 x SiCH3); 
13C NMR (101 MHz, CDCl3) δ 141.4, 131.7, 129.9, 127.2, 121.3, 120.5, 113.7, 104.8, 26.2, 19.4, -4.0; 
IR (film) ?̃? 2959 (m), 2934 (m), 2891 (w), 2860 (m), 1602 (w), 1510 (w), 1460 (m), 1436 (m), 1318 
(w), 1275 (m), 1257 (m), 1152 (s), 1084 (w), 986 (m), 905 (m), 844 (s), 813 (s), 727 (m); 
HRMS (ESI) calcd. for C14H21ClNSi+ [M+H]+ 266.1126; found 266.1123. 
6-bromo-1-(tert-butyldimethylsilyl)-1H-indole (6d) 
 
Following a modified procedure,[4] a solution of the 6-bromo-1H-indole (24) (0.39 g, 2.0 mmol, 1.0 
equiv) in THF (2 mL) was added dropwise to a suspension of NaH (60% suspension in mineral oil, 0.24 
g, 6.0 mmol, 3.0 equiv) in THF (3 mL) under N2 atmosphere at 0 °C. The mixture was allowed to warm 
to room temperature with stirring over 45 minutes to give a near homogenous solution. After re-cooling 
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to 0 °C, tert-butylchlorodimethylsilane (0.45 g, 3.0 mmol, 1.5 equiv) was added as a solution in THF 
(1.5 mL). The mixture was allowed to warm to room temperature and stirred for 12 hours. The mixture 
was diluted with Et2O (25 mL) and water (10 mL). The organic layer was washed with brine (10 mL), 
dried over MgSO4, concentrated under reduced pressure. Purification by flash column chromatography 
(SiO2, eluent pentane) afforded 6-bromo-1-(tert-butyldimethylsilyl)-1H-indole (6d) (0.56 g, 1.8 mmol, 
90% yield) as white solid. 
 
Rf: (SiO2, pentane) 0.40; 
1H NMR (400 MHz, CDCl3) δ 7.63 (s, 1H, ArH), 7.48 (d, J = 8.3 Hz, 1H, ArH), 7.21 (dd, J = 8.4, 1.7 
Hz, 1H, ArH), 7.15 (d, J = 3.2 Hz, 1H, ArH), 6.58 (d, J = 3.2 Hz, 1H, ArH), 0.92 (s, 9H, SiC(CH3)3), 
0.60 (s, 6H, 2 x SiCH3). 
Data match the literature report.[5] 
1-(Tert-butyldimethylsilyl)-5-fluoro-1H-indole (6e) 
 
Following a modified procedure,[4] a solution of 5-fluoro-1H-indole (25) (0.44 g, 3.3 mmol, 1.0 equiv) 
in THF (3 mL) was added dropwise to a suspension of NaH (60% suspension in mineral oil, 0.39 g, 9.8 
mmol, 3.0 equiv) in THF (4 mL) under N2 atmosphere at 0 °C. The mixture was allowed to warm to 
room temperature with stirring over 45 minutes to give a near homogenous solution. After re-cooling to 
0 °C, tert-butylchlorodimethylsilane (0.78 g, 5.2 mmol, 1.6 equiv) was added as a solution in THF (2 
mL). The mixture was allowed to warm to room temperature and stirred for 12 hours. The mixture was 
diluted with Et2O (25 mL) and water (10 mL). The organic layer was washed with brine (10 mL), dried 
over MgSO4, concentrated under reduced pressure. Purification by flash column chromatography (SiO2, 
eluent pentane) afforded 1-(Tert-butyldimethylsilyl)-5-fluoro-1H-indole (6e) (0.75 g, 3.0 mmol, 92% 
yield) as white solid. 
Rf: (SiO2, pentane) 0.38; 
1H NMR (400 MHz, CDCl3) δ 7.41 (dd, J = 9.0, 4.4 Hz, 1H, ArH), 7.28 – 7.23 (m, 1H, ArH), 7.21 (d, 
J = 3.2 Hz, 1H, ArH), 6.89 (td, J = 9.1, 2.7 Hz, 1H, ArH), 6.57 (d, J = 3.1 Hz, 1H, ArH), 0.92 (s, 9H, 
SiC(CH3)3), 0.60 (s, 6H, 2 x SiCH3). 
Data match the literature report.[6] 
1-(Tert-butyldimethylsilyl)-5-iodo-1H-indole (6f) 
 
Following a modified procedure,[4] a solution of the 5-iodo-1H-indole (26) (0.60 g, 2.5 mmol, 1.0 equiv) 
in THF (3 mL) was added dropwise to a suspension of NaH (60% suspension in mineral oil, 0.30 g, 7.4 
mmol, 3.0 equiv) in THF (4 mL) under N2 atmosphere at 0 °C. The mixture was allowed to warm to 
                                                          
5 Kawasaki, I; Yamashita, M; Ohta, S., Chem. Pharm. Bull. 1996, 44, 1831 - 1839. 
6 F.HOFFMANN-LA ROCHE AG, WO2008/152390, 2008, A1. Thiazoliopyrimidines and their use as inhibitors 
of phosphatidylinositol-3 Kinase. 
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room temperature with stirring over 45 minutes to give a near homogenous solution. After re-cooling to 
0 °C, tert-butylchlorodimethylsilane (0.56 g, 3.7 mmol, 1.5 equiv) was added as a solution in THF (2 
mL). The mixture was allowed to warm to room temperature and stirred for 12 hours. The mixture was 
diluted with Et2O (25 mL) and water (10 mL). The organic layer was washed with brine (10 mL), dried 
over MgSO4, concentrated under reduced pressure. Purification by flash column chromatography (SiO2, 
eluent pentane) afforded 1-(Tert-butyldimethylsilyl)-5-iodo-1H-indole (6f) (0.78 g, 2.2 mmol, 88% 
yield) as white solid. 
 
Rf: (SiO2, pentane) 0.32; 
1H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 1.8 Hz, 1H, ArH), 7.39 (dd, J = 8.7, 1.8 Hz, 1H, ArH), 7.29 
(d, J = 8.7 Hz , 1H, ArH), 7.13 (d, J = 3.2 Hz, 1H, ArH), 6.53 (dd, J = 3.2, 0.9 Hz, 1H, ArH), 0.91 (s, 
9H, SiC(CH3)3), 0.59 (s, 6H, 2 x SiCH3). 
Data match the literature report.[7] 
Methyl 1-(tert-butyldimethylsilyl)-1H-indole-6-carboxylate (6g) 
 
Following a modified procedure,[4] a solution of methyl 1H-indole-6-carboxylate (27) (0.53 g, 3.0 mmol, 
1.0 equiv) in THF (3 mL) was added dropwise to a suspension of NaH (60% suspension in mineral oil, 
0.36 g, 9.0 mmol, 3.0 equiv) in THF (4 mL) under N2 atmosphere at 0 °C. The mixture was allowed to 
warm to room temperature with stirring over 45 minutes to give a near homogenous solution. After re-
cooling to 0 °C, tert-butylchlorodimethylsilane (0.72 g, 4.8 mmol, 1.6 equiv) was added as a solution in 
THF (2 mL). The mixture was allowed to warm to room temperature and stirred for 12 hours. The 
mixture was diluted with Et2O (25 mL) and water (10 mL). The organic layer was washed with brine 
(10 mL), dried over MgSO4, concentrated under reduced pressure. Purification by flash column 
chromatography (SiO2, eluent pentane:ethyl acetate 12:1) afforded methyl 1-(tert-butyldimethylsilyl)-
1H-indole-6-carboxylate (6g) (0.77 g, 2.7 mmol, 89% yield) as pale yellow oil. 
 
Rf: (SiO2, pentane:ethyl acetate 20:1) 0.58; 
1H NMR (400 MHz, CDCl3) δ 8.28 (s, 1H, ArH), 7.80 (dd, J = 8.3, 1.4 Hz, 1H, ArH), 7.63 (d, J = 8.2 
Hz, 1H, ArH), 7.34 (d, J = 3.1 Hz, 1H, ArH), 6.65 (dd, J = 3.1, 0.9 Hz, 1H, ArH), 3.93 (s, 3H, CO2CH3), 
0.93 (s, 9H, SiC(CH3)3), 0.65 (s, 6H, 2 x SiCH3). 
Data match the literature report.[8] 
Methyl 1-(tert-butyldimethylsilyl)-1H-indole-5-carboxylate (6h) 
 
Following a modified procedure,[4] a solution of methyl 1H-indole-5-carboxylate (28) (0.35 g, 2.0 mmol, 
1.0 equiv) in THF (3 mL) was added dropwise to a suspension of NaH (60% suspension in mineral oil, 
                                                          
7 Song, Y.-L.; Morin, C., Synlett, 2001, 2, 266–268. 
8 Islam, S., Larrosa, I., Chem. Eur. J. 2013, 19, 15093-15096. 
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0.24 g, 6.0 mmol, 3.0 equiv) in THF (4 mL) under N2 atmosphere at 0 °C. The mixture was allowed to 
warm to room temperature with stirring over 45 minutes to give a near homogenous solution. After re-
cooling to 0 °C, tert-butylchlorodimethylsilane (0.45 g, 3.0 mmol, 1.5 equiv) was added as a solution in 
THF (2 mL). The mixture was allowed to warm to room temperature and stirred for 12 hours. The 
mixture was diluted with Et2O (25 mL) and water (10 mL). The organic layer was washed with brine 
(10 mL), dried over MgSO4, concentrated under reduced pressure. Purification by flash column 
chromatography (SiO2, eluent pentane:ethyl acetate 40:1) afforded methyl 1-(tert-butyldimethylsilyl)-
1H-indole-5-carboxylate (6h) (0.50 g, 1.7 mmol, 86% yield) as white solid. 
 
Rf: (SiO2, pentane:ethyl acetate 40:1) 0.20; 
1H NMR (400 MHz, CDCl3) δ 8.38 (d, J = 1.2 Hz, 1H, ArH), 7.85 (dd, J = 8.7, 1.8 Hz, 1H, ArH), 7.50 
(d, J = 8.7 Hz, 1H, ArH), 7.23 (d, J = 3.2 Hz, 1H, ArH), 6.70 (dd, J = 3.3, 0.9 Hz, 1H, ArH), 3.92 (s, 
3H, CO2CH3), 0.92 (s, 9H, SiC(CH3)3), 0.62 (s, 6H, 2 x SiCH3). 
Data match the literature report.[9] 
1-(Tert-butyldimethylsilyl)-6-(trifluoromethyl)-1H-indole (6i) 
 
Following a modified procedure,[4] a solution of the 6-(trifluoromethyl)-1H-indole (29) (0.37 g, 2.0 
mmol, 1.0 equiv) in THF (2 mL) was added dropwise to a suspension of NaH (60% suspension in 
mineral oil, 0.24 g, 6.0 mmol, 3.0 equiv) in THF (3 mL) under N2 atmosphere at 0 °C. The mixture was 
allowed to warm to room temperature with stirring over 45 minutes to give a near homogenous solution. 
After re-cooling to 0 °C, tert-butylchlorodimethylsilane (0.45 g, 3.0 mmol, 1.5 equiv) was added as a 
solution in THF (1.5 mL). The mixture was allowed to warm to room temperature and stirred for 12 
hours. The mixture was diluted with Et2O (25 mL) and water (10 mL). The organic layer was washed 
with brine (10 mL), dried over MgSO4, concentrated under reduced pressure. Purification by flash 
column chromatography (SiO2, eluent pentane:ethyl acetate 20:1) afforded 1-(Tert-butyldimethylsilyl)-
6-(trifluoromethyl)-1H-indole (6i) (0.54 g, 1.8 mmol, 90% yield) as colorless oil. 
 
Rf: (SiO2, pentane) 0.56; 
1H NMR (400 MHz, CDCl3) δ 7.77 (s, 1H, ArH), 7.70 (d, J = 8.3 Hz, 1H, ArH), 7.34 (dd, J = 7.9, 0.9 
Hz, 1H, ArH), 7.32 (d, J = 3.2 Hz, 1H, ArH), 6.67 (dd, J = 3.1, 0.9 Hz, 1H, ArH), 0.93 (s, 9H, SiC(CH3)3), 
0.63 (s, 6H, 2 x SiCH3). 
Data match the literature report.[10] 
1-(tert-butyldimethylsilyl)-6-methyl-1H-indole (6j) 
 
Following a modified procedure,[4] a solution of 6-methyl-1H-indole (30) (0.26 g, 2.0 mmol, 1.0 equiv) 
in THF (2 mL) was added dropwise to a suspension of NaH (60% suspension in mineral oil, 0.24 g, 6.0 
                                                          
9 Wales, S. M.; Walker, M. M.; Johnson, J. S., Org. Lett. 2013, 15, 2558 – 2561. 
10 Belley, M., Scheigetz, J., Dubé, P., Dolman, S., Synlett 2001, 2, 222 - 225. 
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mmol, 3.0 equiv) in THF (3 mL) under N2 atmosphere at 0 °C. The mixture was allowed to warm to 
room temperature with stirring over 45 minutes to give a near homogenous solution. After re-cooling to 
0 °C, tert-butylchlorodimethylsilane (0.45 g, 3.0 mmol, 1.5 equiv) was added as a solution in THF (1.5 
mL). The mixture was allowed to warm to room temperature and stirred for 12 hours. The mixture was 
diluted with Et2O (25 mL) and water (10 mL). The organic layer was washed with brine (10 mL), dried 
over MgSO4, concentrated under reduced pressure. Purification by flash column chromatography (SiO2, 
eluent pentane:ethyl acetate 40:1) afforded 1-(tert-butyldimethylsilyl)-6-methyl-1H-indole (6j) (0.45 g, 
1.8 mmol, 92% yield) as yellow oil. 
 
Rf: (SiO2, pentane) 0.37; 
1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 8.0 Hz, 1H, ArH), 7.29 (s, 1H, ArH), 7.10 (d, J = 3.2 Hz, 
1H, ArH), 6.94 (dd, J = 7.7, 1.2 Hz, 1H, ArH), 6.55 (dd, J = 3.2, 0.9 Hz, 1H, ArH), 2.46 (s, 3H, CH3), 
0.93 (s, 9H, SiC(CH3)3), 0.59 (s, 6H, 2 x SiCH3); 
13C NMR (101 MHz, CDCl3) δ 141.5, 130.9, 130.4, 129.1, 121.5, 120.1, 113.9, 104.5, 26.4, 22.1, 19.5, 
-3.9; 
IR (film) ?̃? 2956 (m), 2931 (m), 2888 (w), 2857 (m), 1514 (w), 1465 (m), 1286 (m), 1256 (m), 1175 
(w), 1144 (s), 1009 (w), 837 (s), 800 (s), 720 (m); 
HRMS (ESI) calcd. for C15H24NSi+ [M+H]+ 246.1673; found 246.1674. 
1-(Tert-butyldimethylsilyl)-5-methyl-1H-indole (6k) 
 
Following a modified procedure,[4] a solution of the 5-methyl-1H-indole (31) (0.20 g, 1.5 mmol, 1.0 
equiv) in THF (2 mL) was added dropwise to a suspension of NaH (60% suspension in mineral oil, 0.18 
g, 4.5 mmol, 3.0 equiv) in THF (3 mL) under N2 atmosphere at 0 °C. The mixture was allowed to warm 
to room temperature with stirring over 45 minutes to give a near homogenous solution. After re-cooling 
to 0 °C, tert-butylchlorodimethylsilane (0.339 g, 2.25 mmol, 1.5 equiv) was added as a solution in THF 
(1.5 mL). The mixture was allowed to warm to room temperature and stirred for 12 hours. The mixture 
was diluted with Et2O (25 mL) and water (10 mL). The organic layer was washed with brine (10 mL), 
dried over MgSO4, concentrated under reduced pressure. Purification by flash column chromatography 
(SiO2, eluent pentane:ethyl acetate = 40:1) afforded 1-(Tert-butyldimethylsilyl)-5-methyl-1H-indole (6k) 
(0.33 g, 1.3 mmol, 90% yield) as colorless oil. 
Rf: (SiO2, pentane) 0.30; 
1H NMR (400 MHz, CDCl3) δ 7.45 – 7.36 (m, 2H, ArH), 7.14 (d, J = 3.2 Hz, 1H, ArH), 6.98 (dd, J = 
8.5, 1.8 Hz, 1H, ArH), 6.53 (dd, J = 3.2, 0.9 Hz, 1H, ArH), 2.44 (s, 3H, CH3), 0.92 (s, 9H, SiC(CH3)3), 
0.59 (s, 6H, 2 x SiCH3). 
Data match the literature report.[11] 
1-(tert-butyldimethylsilyl)-6-methoxy-1H-indole (6l) 
                                                          
11 Terada, M.; Yokoyama, S.; Sorimachi, K.; Uraguchi, D., Adv. Synth. Catal. 2007, 349, 1863–1867. 
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Following a modified procedure,[4] a solution of 6-methoxy-1H-indole (32) (0.44 g, 3.0 mmol, 1.0 equiv) 
in THF (3 mL) was added dropwise to a suspension of NaH (60% suspension in mineral oil, 0.36 g, 9.0 
mmol, 3.0 equiv) in THF (4 mL) under N2 atmosphere at 0 °C. The mixture was allowed to warm to 
room temperature with stirring over 45 minutes to give a near homogenous solution. After re-cooling to 
0 °C, tert-butylchlorodimethylsilane (0.68 g, 4.5 mmol, 1.5 equiv) was added as a solution in THF (2 
mL). The mixture was allowed to warm to room temperature and stirred for 6 hours. The mixture was 
diluted with Et2O (25 mL) and water (10 mL). The organic layer was washed with brine (10 mL), dried 
over MgSO4, concentrated under reduced pressure. Purification by flash column chromatography (SiO2, 
eluent pentane:ethyl acetate 10:1) afforded 1-(tert-butyldimethylsilyl)-6-methoxy-1H-indole (6l) (0.62 
g, 2.4 mmol, 79% yield) as yellow oil. 
 
Rf: (SiO2, pentane:ethyl acetate 20:1) 0.56; 
1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 8.6 Hz, 1H, ArH), 7.07 (d, J = 3.2 Hz, 1H, ArH), 7.03 (d, J 
= 2.2 Hz, 1H, ArH), 6.80 (dd, J = 8.6, 2.2 Hz, 1H, ArH), 6.53 (d, J = 3.1 Hz, 1H, ArH), 3.84 (s, 3H, 
OCH3), 0.94 (s, 9H, SiC(CH3)3), 0.59 (s, 6H, 2 x SiCH3). 
Data match the literature report.12 
6-Phenyl-1H-indole (33) 
 
Following a reported procedure,[13] a solution of 6-bromoindole (24) (0.47 g, 2.1 mmol, 1 equiv) in 
anhydrous toluene (5 mL) under an N2 atmosphere was treated with Pd(PPh3)4 (0.1 equiv). After stirring 
the mixture for 30 minutes, phenylboronic acid (0.38 g, 3.1 mmol, 1.5 equiv) in anhydrous ethanol (2.5 
mL) were added, followed by saturated NaHCO3 (1.2 mL). The bi-phasic mixture was heated to reflux 
for 24 hours. After cooling to room temperature, the mixture was added to brine and extracted with ethyl 
acetate 2 times. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The residue 
was purified by flash column chromatography (SiO2, eluent pentane:ethyl acetate 7:1) to give 6-Phenyl-
1H-indole (33) (0.11 g, 0.57 mmol, 27% yield) as yellow solid. 
 
Rf: (SiO2, pentane:ethyl acetate 6:1) 0.48; 
1H NMR (400 MHz, CDCl3) δ 8.23 (s, 1H, NH), 7.74 – 7.59 (m, 4H, ArH), 7.48 – 7.37 (m, 3H, ArH), 
7.36 – 7.23 (m, 2H, ArH), 6.59 (s, 1H, ArH). 
Data match the literature report.[14] 
1-(Tert-butyldimethylsilyl)-6-phenyl-1H-indole (6m) 
                                                          
12 Seffar, F.; Llor, N.; Bosch, J.; Amat, M., Synthesis 2001, 2, 267-275. 
13 Van Zandt, M. C.; Jones, M. L.; Gunn, D. E.; Geraci, L. S.; Jones, J. H.;Sawicki, D. R.; Sredy, J.; Jacot, J.; 
Dicioccio, A. T.; Petrova, T.; Mitschler, A.; Podjarny, A. D., J. Med. Chem. 2005, 48, 3141 – 3152 
14 Pascanu, V.; Hansen, P. R.; Gomez, A. B.; Ayats, C.; Platero-Prats, A. E.; Johansson, M. J.; Pericas, M. A.; 
Martin-Matute, B., ChemSusChem 2015, 8, 123-130. 
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Following a modified procedure,[4] a solution of 6-phenyl-1H-indole (33) (0.100 g, 0.520 mmol, 1.0 
equiv) in THF (2 mL) was added dropwise to a suspension of NaH (60% suspension in mineral oil, 62.0 
mg, 1.55 mmol, 3.0 equiv) in THF (3 mL) under N2 atmosphere at 0 °C. The mixture was allowed to 
warm to room temperature with stirring over 45 minutes to give a near homogenous solution. After re-
cooling to 0 °C, tert-butylchlorodimethylsilane (118 mg, 0.780 mmol, 1.5 equiv) was added as a solution 
in THF (1.5 mL). The mixture was allowed to warm to room temperature and stirred for 12 hours. The 
mixture was diluted with Et2O (25 mL) and water (10 mL). The organic layer was washed with brine 
(10 mL), dried over MgSO4, concentrated under reduced pressure. Purification by flash column 
chromatography (SiO2, eluent pentane:ethyl acetate 40:1) afforded 1-(Tert-butyldimethylsilyl)-6-
phenyl-1H-indole (6m) (118 mg, 0.380 mmol, 74% yield) as yellow solid. 
 
Rf: (SiO2, pentane:ethyl acetate 40:1) 0.21;  
Mp: 82.8-83.4 °C; 
1H NMR (400 MHz, CDCl3) δ 7.73 (s, 1H, ArH), 7.69 (d, J = 8.2 Hz, 1H, ArH), 7.63 (dd, J = 8.3, 1.3 
Hz, 2H, ArH), 7.46 (dd, J = 8.4, 6.9 Hz, 2H, ArH), 7.38 (dd, J = 8.2, 1.5 Hz, 1H, ArH), 7.36 – 7.31 (m, 
1H, ArH), 7.22 (d, J = 3.2 Hz, 1H, ArH), 6.64 (dd, J = 3.2, 0.9 Hz, 1H, ArH), 0.98 (s, 9H, SiC(CH3)3), 
0.65 (s, 6H, 2 x SiCH3); 
13C NMR (101 MHz, CDCl3) δ 142.8, 141.6, 134.9, 131.7, 130.7, 128.7, 127.4, 126.4, 120.7, 119.7, 
112.5, 104.6, 26.3, 19.5, -3.9; 
IR (film) ?̃? 3063 (w), 3026 (w), 2952 (m), 2934 (m), 2891 (w), 2860 (m), 1602 (w), 1503 (w), 1466 (m), 
1429 (m), 1312 (m), 1263 (m), 1146 (s), 1078 (w), 986 (w), 819 (s), 788 (m), 757 (m); 
HRMS (ESI) calcd. for C20H26NSi+ [M+H]+ 308.1829; found 308.1831. 
1-(Tert-butyldimethylsilyl)-1,6,7,8-tetrahydrocyclopenta[g]indole (6n) 
 
Following a modified procedure,[4] a solution of 1,6,7,8-tetrahydrocyclopenta[g]indole (34) (0.47 g, 3.0 
mmol, 1.0 equiv) in THF (3 mL) was added dropwise to a suspension of NaH (60% suspension in 
mineral oil, 0.36 g, 9.0 mmol, 3.0 equiv) in THF (4 mL) under N2 atmosphere at 0 °C. The mixture was 
allowed to warm to room temperature with stirring over 45 minutes to give a near homogenous solution. 
After re-cooling to 0 °C, tert-butylchlorodimethylsilane (0.68 g, 4.5 mmol, 1.5 equiv) was added as a 
solution in THF (2 mL). The mixture was allowed to warm to room temperature and stirred for 12 hours. 
The mixture was diluted with Et2O (25 mL) and water (10 mL). The organic layer was washed with 
brine (10 mL), dried over MgSO4, concentrated under reduced pressure. Purification by flash column 
chromatography (SiO2, eluent pentane:ethyl acetate 20:1) afforded (6n) (0.74 g, 2.7 mmol, 91% yield) 
as white solid. 
 
Rf: (SiO2, pentane) 0.40; 
Mp: 53.8-54.8 °C; 
1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 7.8 Hz, 1H, ArH), 7.22 (d, J = 3.2 Hz, 1H, ArH), 7.08 (d, J 
= 7.8 Hz, 1H, ArH), 6.61 (d, J = 3.2 Hz, 1H, ArH), 3.18 (t, J = 7.2 Hz, 2H, CH2CH2CH2), 3.01 (t, J = 
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7.4 Hz, 2H, CH2CH2CH2), 2.12 (p, J = 7.3 Hz, 2H, CH2CH2 CH2), 0.91 (s, 9H, SiC(CH3)3), 0.62 (s, 6H, 
2 x SiCH3); 
13C NMR (101 MHz, CDCl3) δ 139.1, 138.6, 131.8, 131.2, 126.8, 118.7, 117.3, 105.2, 34.5, 33.3, 26.6, 
26.0, 19.6, -1.0; 
IR (film) ?̃? 2952 (m), 2934 (m), 2891 (w), 2860 (m), 1528 (w), 1466 (m), 1411 (m), 1294 (w), 1263 
(m), 1214 (w), 1133 (m), 1084 (m), 1022 (w), 838 (m), 807 (s), 720 (m); 
HRMS (ESI) calcd. for C17H26NSi+ [M+H]+ 272.1829; found 272.1828. 
  
S16 
 
3. Synthesis of the ligands 
(2S,2'S)-Dimethyl 2,2'-((2,2-dimethylmalonyl)bis(azanediyl))bis(3-hydroxypropanoate) (35) 
 
Following a modified procedure,[15] a flame dried flask was put under N2 atmosphere. Serine methylester 
hydrochloride (8.00 g, 51.4 mmol, 2 equiv) was added in the flask, together with 80 mL of dry 
dichloromethane, and the flask was cooled to 0 °C. Triethylamine (14.3 mL, 103 mmol, 4 equiv) was 
added dropwise over 30 minutes. Then, a solution of 2,2-dimethylmalonyl dichloride (3.40 mL, 25.7 
mmol, 1 equiv) in 16 mL of dry dichloromethane was added dropwise over 1 hour. The reaction was 
warmed to room temperature and stirred for 16 hours. The solvent was evaporated, and the residue was 
purified by column chromatography (SiO2, eluent pentane:ethyl acetate:tetrahydrofuran 90:10:0 to 
0:0:100) to afford (2S,2'S)-dimethyl 2,2'-((2,2-dimethylmalonyl)bis(azanediyl))bis(3-
hydroxypropanoate) (35) (8.60 g, 25.7 mmol, quantitative yield) as a colorless oil. 
 
Rf: (SiO2, ethyl acetate) 0.17; 
[α]D20.0 = -164.5 (c = 0.03. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.25 (d, J = 6.8 Hz, 2H, NH), 4.58 (dt, J = 7.3, 3.6 Hz, 2H, NCH), 3.92 
(d, J = 3.8 Hz, 4H, OCH2), 3.77 (s, 6H, CO2CH3), 1.49 (s, 6H, CH3); 
13C NMR (101 MHz, CDCl3) δ 173.7, 170.9, 62.1, 55.2, 52.8, 50.1, 23.2; 
IR (film) ?̃? 3383 (m), 2955 (w), 1741 (s), 1662 (s), 1519 (s), 1464 (w), 1439 (w), 1347 (w), 1284 (w), 
1224 (m), 1180 (m), 1127 (w), 1077 (w); 
HRMS (ESI) calcd for C13H22N2NaO8+ [M+Na]+ 357.1268; found 357.1265. 
(4S,4'S)-Dimethyl 2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4-carboxylate) (9) 
 
Following a modified procedure,[15] a flame dried flask was put under N2 atmosphere. (2S,2'S)-dimethyl 
2,2'-((2,2-dimethylmalonyl)bis(azanediyl))bis(3-hydroxypropanoate) (35) (3.19 g, 9.54 mmol, 1 equiv) 
was added to the flask, followed by 95 mL of dry tetrahydrofuran. The flask was cooled to 0 °C, and 
Burgess’ reagent (5.00 g, 21.0 mmol, 2.2 equiv) was added portionwise. The mixture was then warmed 
to room temperature, and heated at reflux for 2.5 hours. The mixture was then concentrated, the residue 
dissolved in 60 mL of dichloromethane, washed with 20 mL of 5% aqueous solution of NaHCO3, and 
20 mL of brine. The organic layer was dried over MgSO4, filtered and concentrated. The crude was 
purified by column chromatography (SiO2, eluent pentane:ethyl acetate:tetrahydrofuran 20:20:1 to 
0:100:0) to afford (4S,4'S)-dimethyl 2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4-carboxylate) (9) 
(1.77 g, 5.94 mmol, 62% yield) as a pale yellow solid. 
Rf: (SiO2, ethyl acetate) 0.23; 
Mp: 50.6-52.6 °C; 
                                                          
15  Matsumoto, T.; Matsumoto, K., Tanaka, A., EP 2 781 522 A1, optically active bisoxazoline compound, 
asymmetric catalyst, and method for producing optically active cyclopropane compound using said catalyst. 
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[α]D20.0 = -33.2 (c = 0.15. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 4.74 (dd, J = 10.6, 7.8 Hz, 2H, NCH), 4.50 (dd, J = 8.7, 7.8 Hz, 2H, 
OCH2), 4.41 (dd, J = 10.6, 8.7 Hz, 2H, OCH2), 3.76 (s, 6H, CO2CH3), 1.53 (s, 6H, CH3); 
13C NMR (101 MHz, CDCl3) δ 171.6, 171.3, 70.0, 67.9, 52.6, 38.8, 24.2; 
IR (film) ?̃? 2993 (w), 1736 (s), 1644 (s), 1447 (w), 1366 (w), 1286 (w), 1219 (s), 1151 (s), 1120 (m), 
1046 (w), 966 (m), 917 (m), 806 (w), 744 (m) cm-1; 
HRMS (ESI) calcd for C13H18N2NaO6+ [M+Na]+ 321.1057; found 321.1058. 
Grignard addition 
 
General procedure A: 
Grignard preparation: under N2 atmosphere, in a flame dried microwave vial, magnesium turnings (49 
mg, 2.0 mmol, 2 equiv) were added, followed by I2 (cat.) and 1.8 mL of dry tetrahydrofuran. The 
corresponding aryl bromide (1.00 mmol, 1 equiv) was dissolved in 0.3 mL of dry tetrahydrofuran, and 
added dropwise. The mixture was then heated at reflux for 30 seconds, and then allowed to reach room 
temperature. 
Ligand synthesis: Following a modified procedure,[15] under N2 atmosphere in a flame dried flask, a 
solution of (4S,4'S)-dimethyl 2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4-carboxylate) (9) (50 mg, 
0.17 mmol, 1 equiv) in 2.5 mL of dry tetrahydrofuran was added. The flask was cooled to -78 °C with 
a dry ice/acetone bath, and the freshly prepared Grignard (1.00 mmol, 6 equiv) was added dropwise over 
5 minutes. The reaction was stirred at -78 °C for 24 hours allowing it to slowly reach room temperature. 
The reaction was then quenched at 0 °C by adding 2 mL of a saturated aqueous NH4Cl solution. The 
organic layer was separated and the aqueous layer was extracted with 2 mL of dichloromethane. The 
combined organic layers were dried over Na2SO4, filtered and concentrated. An aliquot of the crude was 
purified by preparative TLC (SiO2) for analysis, and the scratched silica was washed with 10 mL of 
ethyl acetate. 
General procedure B: 
Ligand synthesis: Following a modified procedure,[15] under N2 atmosphere in a flame dried flask, a 
solution of (4S,4'S)-dimethyl 2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4-carboxylate) (9) (2.00 g, 
6.70 mmol, 1 equiv) in 100 mL of dry tetrahydrofuran was added. The flask was cooled to -78 °C with 
a dry ice/acetone bath, and a 1 M solution of arylmagnesium bromide in tetrahydrofuran (13.4 mL, 40.2 
mmol, 6 equiv) was added dropwise over 5 minutes. The reaction was stirred at -78 °C for 24 hours 
allowing it to slowly reach room temperature. The reaction was then quenched at 0 °C by adding 50 mL 
of saturated aqueous NH4Cl solution. The organic layer was separated and the aqueous layer was 
extracted with 100 mL of dichloromethane. The combined organic layers were dried over Na2SO4, 
filtered and concentrated. 
General procedure C: 
Grignard preparation: under N2 atmosphere, in a flame dried flask equipped with a reflux condenser, 
magnesium turnings (293 mg, 12.1 mmol, 2 equiv) were added, followed by I2 (cat.) and 10 mL of dry 
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tetrahydrofuran. The aryl bromide was then added dropwise. The mixture was then heated at reflux for 
30 seconds, and then allowed to reach room temperature. 
Ligand synthesis: Following a modified procedure,[15] under N2 atmosphere in a flame dried flask, a 
solution of (4S,4'S)-dimethyl 2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4-carboxylate) (9) (300 
mg, 1.00 mmol, 1 equiv) in 15 mL of dry tetrahydrofuran was added. The flask was cooled to -78 °C 
with a dry ice/acetone bath, and the freshly prepared Grignard (6.03 mmol, 6 equiv) was added dropwise 
over 5 minutes. The reaction was stirred at -78 °C for 24 hours allowing it to slowly reach room 
temperature. The reaction was then quenched at 0 °C by adding 12 mL of saturated aqueous NH4Cl 
solution. The organic layer was separated and the aqueous layer was extracted with 30 mL of 
dichloromethane. The combined organic layers were dried over Na2SO4, filtered and concentrated. The 
crude was purified by column chromatography. 
((4S,4'S)-2,2'-(Propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(diphenylmethanol) (10a) 
 
Following general procedure B, using a phenylmagnesium bromide solution. The crude was purified by 
column chromatography, (SiO2, eluent pentane:ethyl acetate 10:1 to 6:1 to 4:1) to afford ((4S,4'S)-2,2'-
(propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(diphenylmethanol) (10a) (1.40 g, 2.57 mmol, 
38% yield) as a white solid. 
Rf: (SiO2, pentane: ethyl acetate 8:2) 0.28; 
Mp: 115.0-116.5 °C;  
[α]D20.0 = -28.8 (c = 0.3. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 7.0 Hz, 4H, ArH), 7.29 (t, J = 7.7 Hz, 4H, ArH), 7.25 (d, J 
= 6.2 Hz, 4H, ArH), 7.23 – 7.12 (m, 8H, ArH), 5.36 (dd, J = 9.8, 6.8 Hz, 2H, OCH2CHNR), 4.25 (dd, J 
= 8.7, 6.8 Hz, 2H, OCH2CHNR), 4.11 (t, J = 9.2 Hz, 2H, OCH2CHNR), 3.65 (s, 2H, OH), 1.38 (s, 6H, 
CH3); 
13C NMR (101 MHz, CDCl3) δ 172.5, 145.4, 144.4, 128.3, 128.0, 126.7, 126.6, 125.8, 78.8, 72.0, 69.7, 
39.5, 23.6 (one aromatic carbon signal not resolved); 
IR (film) ?̃? 3368 (w), 3005 (w), 1650 (m), 1496 (w), 1447 (m), 1360 (w), 1249 (w), 1212 (w), 1163 (w), 
1120 (m), 1071 (w), 991 (w), 898 (w), 750(s); 
HRMS (ESI) calcd for C35H35N2O4+ [M+H]+ 547.2591; found 547.2598. 
((4S,4'S)-2,2'-(Propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(di-m-tolylmethanol) (10b) 
 
Following general procedure A, using 1-bromo-3-methylbenzene (0.172 g, 1.00 mmol, 6 equiv). The 
weight of the crude was 125 mg. 40 mg of crude were purified for analysis by preparative TLC (SiO2, 
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eluent toluene:ethyl acetate 9:1) to afford (2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-
diyl))bis(di-m-tolylmethanol) (10b) (16.6 mg, 28.0 µmol, 41% calculated yield) as a colorless oil. 
Rf: (SiO2, toluene: ethyl acetate 9:1) 0.4; 
Mp: 119-123 °C; 
[α]D20.0 = -36.27 (c = 0.25. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.34 (s, 2H, ArH), 7.17 (d, J = 4.6 Hz, 6H, ArH), 7.09 – 6.98 (m, 6H, 
ArH), 6.95 (d, J = 7.4 Hz, 2H, ArH), 5.33 (dd, J = 9.8, 6.8 Hz, 2H, OCH2CHNR), 4.26 (dd, J = 8.7, 6.8 
Hz, 2H, OCH2CHNR), 4.12 (dd, J = 9.8, 8.7 Hz, 2H, OCH2CHNR), 3.66 (s, 2H, OH), 2.34 (s, 6H, CH3), 
2.23 (s, 6H, CH3), 1.36 (s, 6H, CH3); 
13C NMR (101 MHz, CDCl3) δ 172.4, 145.4, 144.6, 137.8, 137.3, 128.1, 127.9, 127.5, 127.3, 126.6, 
123.7, 123.0, 78.8, 72.2, 69.8, 39.5, 23.6, 21.7, 21.6 (one aromatic carbon signal not resolved); 
IR (film) ?̃? 3560 (w), 3381 (w), 2966 (w), 2917 (m), 2861 (w), 2242 (w), 1661 (m), 1605 (w), 1481 (m), 
1364 (w), 1302 (w), 1240 (m), 1147 (m), 1122 (m), 986 (m), 912 (S), 850 (w), 776 (m), 733 (S). IR 
3557 (w), 3386 (w), 2921 (w), 2247 (w), 1738 (w), 1660 (m), 1606 (w), 1484 (w), 1363 (w), 1297 (w), 
1244 (w), 1150 (m), 1120 (m), 986 (w), 911 (s), 848 (w), 780 (w), 736 (s); 
HRMS (ESI) calcd for C39H43N2O4+ [M+H]+ 603.3217; found 603.3222.  
((4S,4'S)-2,2'-(Propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(di-p-tolylmethanol) (10c) 
 
Following general procedure A, using 1-bromo-4-methylbenzene (0.172 g, 1.00 mmol, 6 equiv). The 
weight of the crude was 107 mg. 40 mg of crude were purified by preparative TLC (SiO2, eluent 
toluene:ethyl acetate 9:1) to afford (2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(di-p-
tolylmethanol) (10c) (12.9 mg, 21.0 µmol, 34% calculated yield) as a white solid.  
Rf: (SiO2, toluene: ethyl acetate 9:1) 0.3; 
Mp: 88.4-92.1 °C;  
[α]D20.0 = 79.96 (c = 0.24. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.28 (d, J = 8.3 Hz, 4H, ArH), 7.15 (d, J = 8.2 Hz, 4H, ArH), 7.07 (d, J 
= 8.0 Hz, 4H, ArH), 7.03 (d, J = 8.0 Hz, 4H, ArH), 5.33 (dd, J = 9.8, 7.0 Hz, 2H, OCH2CHNR), 4.22 
(dd, J = 8.6, 7.0 Hz, 2H, OCH2CHNR), 4.09 (dd, J = 9.9, 8.6 Hz, 2H, OCH2CHNR), 3.72 (s, 2H, OH), 
2.28 (s, 6H, CH3), 2.26 (s, 6H, CH3), 1.41 (s, 6H, CH3); 
13C NMR (101 MHz, CDCl3) δ 172.5, 143.1, 141.8, 136.1, 136.0, 128.9, 128.8, 126.3, 125.5, 78.4, 72.1, 
69.8, 39.5, 23.7, 21.0, 20.9; 
IR (film) ?̃? 3377 (w), 2993 (w), 2924 (w), 2246 (w), 1660 (m), 1513 (m), 1470 (w), 1411 (w), 1362 (w), 
1247 (w), 1171 (w), 1120 (m), 1022 (w), 986 (m), 912 (s), 818 (m), 785 (w), 736 (s); 
HRMS (ESI) calcd for C39H43N2O4+ [M+H]+ 603.3217; found 603.3223. 
((4S,4'S)-2,2'-(Propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(bis(3,5-
dimethylphenyl)methanol) (10d) 
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Following general procedure C, using 1-bromo-3,5-dimethylbenzene (0.820 mL, 6.03 mmol, 6 equiv). 
The crude was purified by column chromatography (deactivated SiO2, eluent pentane:ethyl acetate 9:1 
+ 1% of triethylamine) to afford (2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(bis(3,5-
dimethylphenyl)methanol) (10d) (316 mg, 0.480 mmol, 48% yield) as a white solid. 
Rf: (SiO2, pentane: ethyl acetate 8:2) 0.5; 
Mp: 108.1-112.6 °C; 
[α]D20.0 = -4.46 (c = 0.5. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.10 (s, 4H, ortho-ArH), 6.93 (s, 4H, ortho-ArH), 6.83 (s, 2H, para-
ArH), 6.75 (s, 2H, para-ArH), 5.27 (dd, J = 9.8, 6.5 Hz, 2H, OCH2CHNR), 4.29 (app t, J = 7.7 Hz, 2H, 
OCH2CHNR), 4.13 (app t, J = 9.2 Hz, 2H, OCH2CHNR), 3.49 (br s, 2H, OH), 2.29 (s, 12H, CH3), 2.12 
(s, 12H, CH3), 1.29 (s, 6H, CH3); 
13C NMR (101 MHz, CDCl3) δ 172.0, 145.0, 144.8, 137.5, 137.0, 128.5, 128.4, 124.6, 124.0, 79.0, 72.3, 
69.9, 39.4, 23.4, 21.5, 21.4; 
IR (film) ?̃? 3401 (w), 2917 (w), 2246 (w), 1660 (w), 1603 (w), 1471 (w), 1366 (w), 1244 (w), 1150 (w), 
1119 (m), 985 (w), 910 (m), 854 (w), 732 (s); 
HRMS (ESI) calcd for C43H51N2O4+ [M+H]+ 659.3843; found 659.3846. 
((4S,4'S)-2,2'-(Propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(bis(3,5-di-tert-
butylphenyl)methanol) (10e) 
 
Following general procedure A, using 1-bromo-3,5-di-tert-butylbenzene (0.271 g, 1.00 mmol, 6 equiv). 
The weight of the crude was 246 mg. 40 mg of crude were purified by preparative TLC (SiO2, eluent 
toluene:ethyl acetate 9:1) to afford (2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-
diyl))bis(bis(3,5-di-tert-butylphenyl)methanol) (10e) (14.3 mg, 14.0 µmol, 53% calculated yield) as a 
colorless oil. 
Rf: (SiO2, toluene: ethyl acetate 9:1) 0.54; 
[α]D20.0 = 8.96 (c = 0.4. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 1.8 Hz, 4H, ArH), 7.23 (m, 8H, ArH), 5.24 (t, J = 9.2 Hz, 
2H, OCH2CHNR), 4.15 (dd, J = 9.2, 1.8 Hz, 4H, OCH2CHNR), 2.89 (s, 2H, OH), 1.45 (s, 6H, CH3), 
1.27 (s, 36H, C(CH3)3), 1.26 (s, 36H, C(CH3)3); 
13C NMR (101 MHz, CDCl3) δ 171.7, 150.0, 149.6, 145.3, 143.2, 121.3, 120.5, 120.4, 120.3, 79.3, 73.7, 
70.4, 39.2, 34.9, 34.8, 31.5, 24.3 (one aliphatic carbon signal is not resolved); 
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IR (film) ?̃? 3528 (w), 3071 (w), 2962 (s), 2906 (m), 2868 (m), 2246 (w), 1661 (m), 1599 (m), 1475 (m), 
1393 (w), 1363 (m), 1250 (m), 1202 (w), 1178 (w), 1152 (w), 1121 (m), 1071 (w), 983 (w), 911 (m), 
878 (w), 847 (w), 824 (w), 737 (s); 
HRMS (ESI) calcd for C67H99N2O4+ [M+H]+ 995.7599; found 995.7595. 
((4S,4'S)-2,2'-(Propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(bis(3,5-
dimethoxyphenyl)methanol) (10f) 
 
Following general procedure A, using 1-bromo-3,5-dimethoxybenzene (0.218 g, 1.00 mmol, 6 equiv). 
The weight of the crude was 154 mg. 35 mg of crude were purified by preparative TLC (SiO2, eluent 
heptane:ethyl acetate 6:4). The obtained product was resubjected to preparative TLC (SiO2, eluent 
heptane:ethyl acetate 6:4) to afford (2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-
diyl))bis(bis(3,5-dimethoxyphenyl)methanol) (10f) (11.0 mg, 14.0 µmol, 41% calculated yield) as a 
colorless oil. 
Rf: (SiO2, pentane:ethyl acetate 6:4) 0.13; 
[α]D20.0 = -30.24 (c = 0.47. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 6.58 (dd, J = 6.0, 2.3 Hz, 8H, ArH), 6.27 (dt, J = 9.9, 2.2 Hz, 4H, ArH), 
5.21 (dd, J = 9.8, 7.2 Hz, 2H, OCH2CHNR), 4.24 (dd, J = 8.7, 7.1 Hz, 2H, OCH2CHNR), 4.16 (dd, J = 
9.8, 8.7 Hz, 2H, OCH2CHNR), 3.75 (s, 12H, OCH3), 3.70 (s, 12H, OCH3), 1.40 (s, 6H, CH3); 
13C NMR (101 MHz, CDCl3) δ 172.4, 160.5, 160.3, 147.7, 146.6, 105.2, 104.4, 98.5, 98.4, 78.9, 72.3, 
69.9, 55.3, 55.1, 39.4, 23.6; 
IR (film) ?̃? 3442 (w), 3000 (w), 2942 (w), 2838 (w), 2254 (w), 1661 (w), 1600 (s), 1462 (m), 1426 (m), 
1345 (w), 1294 (m), 1249 (w), 1206 (s), 1156 (s), 1121 (w), 1063 (m), 983 (w), 919 (m), 838 (w), 737 
(s); 
HRMS (ESI) calcd for C43H51N2O12+ [M+H]+ 787.3437; found 787.3433. 
((4S,4'S)-2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(bis(3,5-
bis(trifluoromethyl)phenyl)methanol) (10g) 
 
Following general procedure A, using 1-bromo-3,5-bis(trifluoromethyl)benzene (0.295 g, 1.00 mmol, 6 
equiv). The weight of the crude was 239 mg. 40 mg of crude were purified by preparative TLC (SiO2, 
eluent toluene:ethyl acetate 9:1) to afford (2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-
diyl))bis(bis(3,5-bis(trifluoromethyl)phenyl)methanol) (10g) (25.3 mg, 23.0 µmol, 83% calculated 
yield) as an off-white solid. 
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Rf: (silica, toluene: ethyl acetate 9:1) 0.59; 
Mp: 53.8-58.2 °C. 
[α]D20.0 = -99.03 (c = 0.33. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 1.6 Hz, 4H, ArH), 7.82 (s, 6H, ArH), 7.77 (s, 2H), 5.36 (dd, 
J = 9.8, 7.7 Hz, 2H, OCH2CHNR), 4.19 (app t, J = 9.4 Hz, 2H, OCH2CHNR), 4.10 (dd, J = 9.0, 7.7 Hz, 
2H, OCH2CHNR), 3.51 (br s, 2H, OH), 1.43 (s, 6H, CH3); 
13C NMR (101 MHz, CDCl3) δ 174.1, 146.3, 145.0, 132.3 (q, J = 33.3 Hz), 131.8 (q, J = 34.3 Hz), 127.0 
(m), 126.0 (m), 123.0 (q, J = 273.7 Hz), 123.0 (q, J = 273.7 Hz), 122.1 (m), 122.1 (m), 77.9, 71.7, 69.3, 
39.7, 23.3; 
19F NMR (376 MHz, CDCl3) δ -62.9, -63.0; 
IR (film) ?̃? 3381 (w), 1662 (w), 1632 (w), 1472 (w), 1375 (m), 1279 (s), 1171 (s), 1129 (s), 975 (w), 
902 (m), 847 (w), 812 (w), 739 (m), 711 (m); 
HRMS (ESI) calcd for C43H27F24N2O4+ [M+H]+ 1091.1582; found 1091.1595. 
((4S,4'S)-2,2'-(Propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(di(naphthalen-2-
yl)methanol) (10h) 
 
Following general procedure A, using 2-bromonaphthalene (0.208 g, 1.00 mmol, 6 equiv). The weight 
of the crude was 194 mg. 40 mg of crude were purified by preparative TLC (SiO2, eluent toluene:ethyl 
acetate 9:1) to afford (2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(di(naphthalen-2-
yl)methanol) (10h) (12.1 mg, 16.0 µmol, 47% calculated yield) as an off-white solid. 
Rf: (SiO2, toluene: ethyl acetate 9:1) 0.38; 
Mp: 139-147 °C; 
[α]D20.0 = -246.12 (c = 0.19. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 8.16 (s, 2H, ArH), 8.00 (s, 2H, ArH), 7.95 (d, J = 8.1 Hz, 2H, ArH), 7.84 
– 7.72 (m, 4H, ArH), 7.67 (dd, J = 8.4, 5.4 Hz, 4H, ArH), 7.55 – 7.23 (m, 12H, ArH), 6.98 – 6.91 (m, 
2H, ArH), 5.63 (dd, J = 9.8, 6.7 Hz, 2H, OCH2CHNR), 4.40 (dd, J = 8.7, 6.7 Hz, 2H, OCH2CHNR), 
4.16 (t, J = 9.3 Hz, 2H, OCH2CHNR), 4.11 (s, 2H, OH), 1.41 (s, 6H, CH3); 
13C NMR (101 MHz, CDCl3) δ 172.7, 142.2, 141.4, 133.0, 132.8, 132.3, 132.2, 128.6, 128.4, 128.0, 
127.6, 127.4, 127.3, 126.1, 126.0, 125.8, 125.7, 125.7, 125.1, 124.5, 124.4, 79.0, 71.6, 69.8, 39.6, 23.6; 
IR (film) ?̃? 3635 (w), 3557 (w), 3363 (w), 3057 (w), 2939 (w), 2248 (w), 1923 (w), 1654 (m), 1600 (w), 
1507 (w), 1472 (w), 1363 (w), 1245 (w), 1154 (w), 1120 (m), 1020 (w), 987 (w), 908 (s), 858 (w), 821 
(m), 795 (m), 733 (s); 
HRMS (ESI) calcd for C51H43N2O4+ [M+H]+ 747.3217; found 747.3219. 
(4S,4'S)-2,2'-(Propane-2,2-diyl)bis(4-((benzyloxy)diphenylmethyl)-4,5-dihydrooxazole) (11a) 
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Following a modified procedure,[16] under N2 atmosphere, in a flame dried flask, (2,2'-(propane-2,2-
diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(diphenylmethanol) (10a) (100 mg, 0.183 mmol, 1 equiv) was 
added, followed by dry dimethylformamide (0.4 mL). The flask was cooled at 0 °C, and sodium hydride 
(60% dispersion in mineral oil, 18.0 mg, 0.439 mmol, 2.4 equiv) was added. The reaction mixture was 
stirred for 1 hour at 0 °C. Then, benzyl bromide (52.0 µL, 0.439 mmol, 2.4 equiv) was added dropwise. 
The reaction was warmed to room temperature and stirred for 16 hours. The reaction was then quenched 
by the addition of 5 mL of saturated aqueous NH4Cl solution, and extracted with diethyl ether (3x5 mL). 
The combined organic phases were dried over Na2SO4, filtered and evaporated. The residue was purified 
by column chromatography (SiO2, eluent pentane:ethyl acetate 49:1) to afford 2,2'-(propane-2,2-
diyl)bis(4-((benzyloxy)diphenylmethyl)-4,5-dihydrooxazole) (11a) (73.0 mg, 0.100 mmol, 55% yield) 
as a white solid. 
Rf: (SiO2, toluene: ethyl acetate 9:1) 0.23; 
Mp: 84.2-92.4 °C; 
[α]D20.0 = 82.34 (c = 0.15. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.68 – 7.61 (m, 4H, ArH), 7.44 – 7.38 (m, 4H), 7.36 – 7.26 (m, 15H, 
ArH), 7.26 – 7.16 (m, 7H, ArH), 5.26 (dd, J = 10.1, 7.4 Hz, 2H, OCH2CHNR), 4.41 – 4.32 (m, 4H, 
OCH2CHNR + OCH2Ph), 4.20 (d, J = 11.8 Hz, 2H, OCH2Ph), 4.06 (dd, J = 10.1, 8.8 Hz, 2H, 
OCH2CHNR), 0.98 (s, 6H, CH3); 
13C NMR (101 MHz, CDCl3) δ 169.7, 143.5, 141.3, 139.1, 129.0, 128.6, 128.2, 127.9, 127.3, 127.2, 
127.01, 126.95, 126.91, 83.9, 70.2, 69.1, 65.6, 38.5, 23.1; 
IR (film) ?̃? 4051 (w), 3062 (w), 3030 (w), 2905 (w), 2249 (w), 1953 (w), 1741 (w), 1655 (s), 1604 (w), 
1544 (w), 1495 (m), 1449 (m), 1386 (w), 1313 (w), 1261 (m), 1220 (w), 1152 (m), 1121 (m), 1063 (s), 
1032 (m), 985 (m), 910 (s), 843 (w), 735 (s); 
HRMS (ESI) calcd for C49H47N2O4+ [M+H]+ 727.3530; found 727.3534. 
  
                                                          
16 Wang, S.-H.; Chein, R.-J., Tetrahedron 2016, 72, 2607-2615. 
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4. Optimization of the enantioselective desymmetrization 
General procedure D: 
 
In a glovebox, an oven dried microwave vial was charged with copper(II) triflate (3.6 mg, 10 µmol, 0.2 
equiv), and ligand (3.5 mg, 12 µmol, 0.24 equiv). The vial was taken out of the glovebox and put under 
N2 atmosphere. 0.5 mL of dry dichloromethane was added and the suspension was stirred vigorously for 
2 hours. Then, a solution of dimethyl 2,4-dibenzoyl-3-oxo-2,4-diazabicyclo[3.1.0]hexane-6,6-
dicarboxylate (20) (21.1 mg, 50.0 µmol, 1 equiv) and the indole (60.0 µmol, 1.2 equiv) in 0.5 mL of dry 
dichloromethane was added. The reaction was stirred at room temperature for 16 hours, diluted with 0.5 
mL of ethyl acetate and then filtered on a pad of SiO2, eluting with 5 mL of ethyl acetate. The solution 
was concentrated and subjected to preparative TLC (SiO2) with the specified eluent. The scratched SiO2 
was washed with 10 mL of ethyl acetate. The solvent was evaporated to afford the product. 
Table S1. Screening of N-substituents of the indole. 
entry R Yield (%) er 
1 H 50 46:54 
2 Me 65 46:54 
3 TBS 60 42:58 
 
 
General procedure E: 
 
In a glovebox, an oven dried microwave vial was charged with copper(II) chloride (1.3 mg, 10 µmol, 
0.2 equiv), MX (4.0 µmol, 0.4 equiv), and ligand (24 µmol, 0.24 equiv). The vial was protected from 
light with aluminum foil, taken out of the glovebox and put under N2 atmosphere. 0.5 mL of dry solvent 
S25 
 
was added and the suspension was stirred vigorously for 2 hours. Then, a solution of cyclopropane (50.0 
µmol, 1 equiv) and 1-(tert-butyldimethylsilyl)-1H-indole (6a) (13.9 mg, 60.0 µmol, 1.2 equiv) in 0.5 
mL of dry solvent were added. The reaction was stirred at room temperature for 16 hours, diluted with 
0.5 mL of ethyl acetate and then filtered on a pad of SiO2, eluting with 5 mL of ethyl acetate. The 
solution was concentrated and subjected to preparative TLC (SiO2) with heptane:ethyl acetate 65:35 as 
eluent. The scratched SiO2 was washed with 10 mL of ethyl acetate. The solvent was evaporated to 
afford the product. 
Table S2. Screening of protecting groups on cyclopropane, ligands, counterions and solvents. 
entry R Ligand MX Solvent Yield (%) er 
1 PhCO 8 AgSbF6 DCM 80 39.5:60.5 
2 PhCO 8 AgSbF6 CDCl3 74 29:71 
3 PhCO 8 AgSbF6 Toluene[a] 52 19.4:80.6 
4 MeCO[2] 8 AgSbF6 Toluene 39 39.5:60.5 
5 tBuCO 8 AgSbF6 Toluene 70 25:75 
6 tBuCO 39 AgSbF6 Toluene 77 46:54 
7 tBuCO 40 AgSbF6 Toluene 71 61:39 
8 tBuCO 41 AgSbF6 Toluene 68 57:43 
9 tBuCO 42 AgSbF6 Toluene 91 42:58 
10 tBuCO 43 AgSbF6 p-xylene 72 42:58 
11 tBuCO 8 AgOTf p-xylene 42 29:71 
12 tBuCO 8 AgBF4 Toluene 44 28:72 
13 tBuCO 8 AgClO4 Toluene 45 27.5:72.5 
14 tBuCO 8 AgPF6 Toluene 44 28:72 
15 tBuCO 8 AgNTF2 Toluene 25 37.5:62.5 
16 tBuCO 8 NaBARF Toluene No conversion - 
17 tBuCO 8 AgSbF6 CCl4 45  20:80 
18 tBuCO 8 AgSbF6 DCM 74 37.5:62.5 
19 tBuCO 8 AgSbF6 Trifluorotoluene 83 34:66 
20 tBuCO 8 AgSbF6 o-xylene 79 26.5:73.5 
21 tBuCO 8 AgSbF6 m-xylene 87 25:75 
22 tBuCO 8 AgSbF6 p-xylene 86 24:76 
23 tBuCO 8 AgSbF6 Benzene 73 21.5:78.5 
24 tBuCO 8 AgSbF6 Chlorobenzene 75 30:70 
[a]Using 5 mL of solvent. [b]The cyclopropane was added as a solid. 
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Dimethyl 2-(1,3-dibenzoyl-5-(1H-indol-3-yl)-2-oxoimidazolidin-4-yl)malonate (37a) 
 
Following general procedure D, using 1H-indole (21) (7.0 mg, 60 µmol, 1.2 equiv). Preparative TLC 
using eluent 1:1 heptane:ethyl acetate afforded dimethyl 2-(1,3-dibenzoyl-5-(1H-indol-3-yl)-2-
oxoimidazolidin-4-yl)malonate (37a) (18.7 mg, 35.0 µmol, 69% yield) as a grey solid. Chiral HPLC 
conditions: er = 54:46; Chiralpak IB 80:20 Hexane/iPrOH, 1.0 mL/min, 60 min. tr (major) = 23.0 min. 
and tr (minor) = 31.7 min. λ = 250 cm-1. 
 
Rf: (SiO2, pentane:ethyl acetate 6:4) 0.28; 
Mp: 99.4-102.9 °C; 
1H NMR (400 MHz, CDCl3) δ 8.30 (s, 1H, NH), 7.80 – 7.75 (m, 1H, ArH), 7.67 – 7.63 (m, 2H, ArH), 
7.56 – 7.52 (m, 2H, ArH), 7.51 – 7.46 (m, 1H, ArH), 7.41 – 7.34 (m, 4H, ArH), 7.32 – 7.26 (m, 3H, 
ArH), 7.25 – 7.18 (m, 2H, ArH), 6.14 (d, J = 3.6 Hz, 1H, indole-CH), 5.28 (dd, J = 4.2, 3.6 Hz, 1H, 
indole-CH-CH), 4.46 (d, J = 4.2 Hz, 1H, CH(CO2CH3)2), 3.80 (s, 3H, CO2CH3), 3.64 (s, 3H, CO2CH3); 
13C NMR (101 MHz, CDCl3) δ 170.1, 169.2, 167.2, 166.9, 150.4, 136.7, 133.9, 133.7, 132.2, 131.9, 
128.9, 127.9, 127.8, 124.5, 124.0, 122.6, 120.5, 118.7, 113.5, 111.8, 57.2, 53.1, 52.8, 52.5, 51.3 (one 
aromatic carbon signal is not resolved); 
IR (film) ?̃? 3399 (w), 1758 (s), 1679 (s), 1444 (w), 1339 (m), 1277 (s), 1188 (m), 1031 (w), 910 (w); 
HRMS (ESI) calcd for C30H25N3O7 [M+] 539.1687; found 539.1684. 
Dimethyl 2-(1,3-dibenzoyl-5-(1-methyl-1H-indol-3-yl)-2-oxoimidazolidin-4-yl)malonate (37b) 
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Following general procedure D, using 1-methyl-1H-indole (36) (7.9 mg, 60 µmol, 1.2 equiv). 
Preparative TLC using eluent 1:1 heptane:ethyl acetate afforded dimethyl 2-(1,3-dibenzoyl-5-(1-
methyl-1H-indol-3-yl)-2-oxoimidazolidin-4-yl)malonate (37b) (17.0 mg, 31.0 µmol, 61% yield) as a 
yellow solid. Chiral HPLC conditions: er = 54:46; Chiralpak IB 80:20 Hexane/iPrOH, 1.0 mL/min, 60 
min. tr (major) = 20.1 min. and tr (minor) = 26.4 min. λ = 260 cm-1. 
 
Rf: (SiO2, pentane:ethyl acetate 6:4) 0.40; 
Mp: 103.8-107.5 °C; 
1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 8.0 Hz, 1H, ArH), 7.68 – 7.64 (m, 2H, ArH), 7.55 – 7.52 (m, 
2H, ArH), 7.51 – 7.46 (m, 1H, ArH), 7.42 – 7.37 (m, 3H, ArH), 7.35 – 7.26 (m, 4H, ArH), 7.23 – 7.17 
(m, 2H, ArH), 6.11 (d, J = 3.4 Hz, 1H, indole-CH), 5.28 (dd, J = 4.2, 3.4 Hz, 1H, indole-CH-CH), 4.44 
(d, J = 4.2 Hz, 1H, CH(CO2CH3)2), 3.79 (s, 3H, CO2CH3), 3.77 (s, 3H, CO2CH3), 3.67 (s, 3H, NCH3); 
13C NMR (101 MHz, CDCl3) δ 170.1, 169.1, 167.2, 166.9, 150.4, 137.5, 133.9, 133.7, 132.1, 131.9, 
128.9, 128.5, 127.9, 127.7, 125.0, 122.1, 120.1, 118.8, 111.8, 109.9, 57.3, 53.1, 52.8, 52.5, 51.3, 32.9 
(one aromatic carbon signal is not resolved); 
IR (film) ?̃? 2949 (w), 1758 (s), 1679 (s), 1444 (w), 1318 (m), 1266 (s), 1198 (m), 1036 (w), 916 (w); 
HRMS (ESI) calcd for C31H27N3O7 [M+] 553.1844; found 553.1844. 
Dimethyl 2-(1,3-dibenzoyl-5-(1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-2-oxoimidazolidin-4-
yl)malonate (37c) 
 
Following general procedure E, using dimethyl 2,4-dibenzoyl-3-oxo-2,4-diazabicyclo[3.1.0]hexane-
6,6-dicarboxylate (20) (21.1 mg, 50.0 µmol, 1 equiv). Preparative TLC using eluent 55:45 heptane:ethyl 
acetate afforded dimethyl 2-(1,3-dibenzoyl-5-(1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-2-
oxoimidazolidin-4-yl)malonate (37c) (16.9 mg, 26.0 µmol, 52% yield) as a white solid. Chiral HPLC 
conditions: er = 80.6:19.4; Chiralpak IB 95:5 Hexane/iPrOH, 0.5 mL/min, 31 min. tr (major) = 15.7 min. 
and tr (minor) = 19.1 min. λ = 260 cm-1. 
 
Rf: (SiO2, pentane:ethyl acetate1:1) 0.62; 
[α]D20.0 = 21.1 (c = 0.31. CHCl3); 
Mp: 87.6-88.7 °C; 
1H NMR (400 MHz, CDCl3) δ 7.80 – 7.75 (m, 1H, ArH), 7.66 – 7.62 (m, 2H, ArH), 7.55 – 7.46 (m, 4H, 
ArH), 7.42 – 7.36 (m, 3H, ArH), 7.32 – 7.27 (m, 3H, ArH), 7.23 – 7.17 (m, 2H, ArH), 6.13 (d, J = 3.4 
Hz, 1H, indole-CH), 5.26 – 5.21 (m, 1H, indole-CH-CH), 4.45 (d, J = 4.1 Hz, 1H, CH(CO2CH3)2), 3.79 
(s, 3H, CO2CH3), 3.67 (s, 3H, CO2CH3), 0.92 (s, 9H, SiC(CH3)3), 0.61 (s, 6H, SiCH3); 
13C NMR (101 MHz, CDCl3) δ 170.2, 169.0, 167.2, 166.9, 150.5, 142.0, 134.1, 133.8, 132.2, 131.8, 
130.6, 128.9, 128.8, 128.0, 127.9, 127.8, 122.1, 120.5, 118.8, 115.4, 114.5, 57.2, 53.1, 52.8, 52.6, 51.4, 
26.3, 19.4, -3.9 (one SiCH3 carbon signal is not resolved); 
IR (film) ?̃? 2952 (w), 2928 (w), 1787 (m), 1733 (s), 1691 (s), 1446 (w), 1327 (s), 1279 (s), 1225 (s), 
1166 (s), 1082 (w), 909 (w), 825 (w); 
HRMS (ESI) calcd. for C36H39N3NaO7Si+ [M+Na]+ 676.2449; found 676.2452. 
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Dimethyl 2-(1,3-diacetyl-5-(1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-2-oxoimidazolidin-4-
yl)malonate (38) 
 
Following general procedure E, using dimethyl 2,4-diacetyl-3-oxo-2,4-diazabicyclo[3.1.0]hexane-6,6-
dicarboxylate (19) (14.9 mg, 50.0 µmol, 1 equiv). Preparative TLC using eluent 65:35 heptane:ethyl 
acetate afforded dimethyl 2-(1,3-diacetyl-5-(1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-2-
oxoimidazolidin-4-yl)malonate (38) (10.4 mg, 20.0 µmol, 39% yield) as a colorless oil. Chiral HPLC 
conditions: er = 60.5:39.5; Chiralpak IB 95:5 Hexane/iPrOH, 0.5 mL/min, 31 min. tr (major) = 8.0 min. 
and tr (minor) = 10.4 min. λ = 260 cm-1. 
 
Rf: (SiO2, pentane:ethyl acetate 6:4) 0.67; 
1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 8.2 Hz, 1H, ArH), 7.42 – 7.36 (m, 1H, ArH), 7.19 (s, 1H, 
ArH), 7.18 – 7.13 (m, 1H, ArH), 7.13 – 7.08 (m, 1H, ArH), 5.80 (d, J = 1.8 Hz, 1H, indole-CH), 4.84 
(dd, J = 4.1, 1.9 Hz, 1H, indole-CH-CH), 4.24 (d, J = 4.1 Hz, 1H, CH(CO2CH3)2), 3.75 (s, 3H, CO2CH3), 
3.72 (s, 3H, CO2CH3), 2.66 (s, 3H, COCH3), 2.48 (s, 3H, COCH3), 0.90 (s, 9H, SiC(CH3)3), 0.59 (s, 3H, 
SiCH3), 0.59 (s, 3H, SiCH3); 
13C NMR (101 MHz, CDCl3) δ 170.8, 169.6, 167.1, 166.9, 152.1, 141.9, 130.7, 127.6, 121.8, 120.4, 
118.4, 115.7, 114.5, 56.6, 52.9, 52.8, 51.8, 51.4, 26.2, 24.6, 24.4, 19.5, -3.9 (one SiCH3 carbon signal is 
not resolved); 
IR (film) ?̃? 2958 (w), 2934 (w), 2862 (w), 1757 (s), 1703 (m), 1452 (w), 1369 (m), 1255 (s), 1166 (m), 
1028 (w), 975 (w), 915 (w), 843 (w), 813 (w); 
HRMS (ESI) calcd. for C26H36N3O7Si+ [M+H]+ 530.2317; found 530.2327. 
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5. Scope of the enantioselective desymmetrization 
General procedure F: 
 
In a glovebox, an oven dried microwave vial was charged with copper(II) chloride (2.7 mg, 20 µmol, 
0.2 equiv) and silver hexafluoroantimonate(V) (13.1 mg, 38.0 µmol, 0.38 equiv). The vial was protected 
from light with aluminum foil, taken out of the glovebox and put under N2. A solution of ligand 10d 
(15.8 mg, 24.0 µmol, 0.24 equiv) in 2 mL of dry toluene was added in the vial, and the suspension was 
stirred vigorously for 2 hours. Then the vial was cooled at the indicated temperature in a cryostat. After 
10 minutes, a solution of the indole/pyrrole 6 (0.100 mmol, 1 equiv) and cyclopropane 2 (57.4 mg, 0.150 
mmol, 1.5 equiv) in 2 mL of dry toluene was added dropwise. The reaction was stirred at the same 
temperature for the indicated time, diluted with 2 mL of a mixture of pentane:ethyl acetate 1:1 and then 
filtered on a pad of SiO2, eluting with the same mixture (15 mL). The solution was concentrated and 
subjected to preparative TLC (SiO2) with the specified eluent. The scratched SiO2 was washed with 10 
mL of ethyl acetate to afford the product. 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-2-oxo-1,3-dipivaloylimidazolidin-4-
yl)malonate (7a) 
 
Following general procedure F, 1-(tert-butyldimethylsilyl)-1H-indole (6a) (23.1 mg, 0.100 mmol, 1 
equiv) and cyclopropane 2 were stirred at -50 °C for 18 hours and 30 minutes. Preparative TLC using 
eluent 9:1 toluene:ethyl acetate afforded dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-2-
oxo-1,3-dipivaloylimidazolidin-4-yl)malonate (7a) (49.0 mg, 80.0 µmol, 80% yield) as a white solid. 
Chiral HPLC conditions: er = 94.2:5.8; Chiralpak IB 97:3 Hexane/iPrOH, 1.0 mL/min, 30 min. tr (minor) 
= 14.7 min. and tr (major) = 16.1 min. λ = 280 cm-1. 
 
Rf: (SiO2, pentane:ethyl acetate 8:2) 0.6; 
Mp: 72.3-73.2 °C; 
[α]D20.0 = -22.7 (c = 0.24. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.80 – 7.74 (m, 1H, ArH), 7.48 – 7.43 (m, 1H, ArH), 7.18 – 7.09 (m, 2H, 
ArH), 7.00 (s, 1H, ArH), 5.90 (s, 1H, indole-CH), 4.79 (dd, J = 4.6, 1.2 Hz, 1H, indole-CH-CH), 4.14 
(d, J = 4.6 Hz, 1H, CH(CO2CH3)2), 3.75 (s, 6H, 2 x CO2CH3), 1.42 (s, 9H, C(CH3)3), 1.35 (s, 9H, 
C(CH3)3), 0.87 (s, 9H, SiC(CH3)3), 0.56 (s, 3H, SiCH3), 0.54 (s, 3H, SiCH3); 
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13C NMR (101 MHz, CDCl3) δ 179.0, 177.5, 167.2, 167.2, 149.6, 141.8, 128.3, 128.2, 121.9, 120.1, 
119.3, 117.1, 114.1, 58.7, 53.0, 52.8, 52.8, 51.7, 41.8, 41.8, 26.3, 26.2, 19.5, -4.0, -4.0; 
IR (film) ?̃? 2955 (w), 2934 (w), 2860 (w), 1758 (m), 1684 (w), 1454 (w), 1318 (w), 1261 (m), 1209 (w), 
1156 (s), 1010 (w), 968 (w), 916 (w), 843 (w), 817 (w); 
HRMS (ESI) calcd. for C32H47N3NaO7Si+ [M+Na]+ 636.3075; found 636.3077. 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-5-chloro-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7b) 
 
Following general procedure F, 1-(tert-butyldimethylsilyl)-5-chloro-1H-indole (6b) (26.6 mg, 0.100 
mmol, 1 equiv) and cyclopropane 2 were stirred at -50 °C for 42 hours. Preparative TLC using eluent 
9:1 toluene:ethyl acetate afforded dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-5-chloro-1H-indol-3-yl)-2-
oxo-1,3-dipivaloylimidazolidin-4-yl)malonate (7b) (52.5 mg, 81.0 µmol, 81% yield) as a white solid. 
Chiral HPLC conditions: er = 95:5; Chiralpak IA 98:2 Hexane/iPrOH, 1.0 mL/min, 31 min. tr (minor) = 
5.9 min. and tr (major) = 7.2 min. λ = 260 cm-1. 
 
Rf: (SiO2, toluene:ethyl acetate 9:1) 0.51; 
Mp: 131.2-132.0 °C; 
[α]D20.0 = -29.9 (c = 0.30. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 2.0 Hz, 1H, ArH), 7.35 (d, J = 8.8 Hz, 1H, ArH), 7.10 (dd, 
J = 8.8, 2.1 Hz, 1H, ArH), 7.04 (s, 1H, ArH), 5.84 (s, 1H, indole-CH), 4.74 (d, J = 4.5 Hz, 1H, indole-
CH-CH), 4.16 (d, J = 4.5 Hz, 1H, CH(CO2Me)2), 3.78 (s, 3H, CO2CH3), 3.75 (s, 3H, CO2CH3),1.44 (s, 
9H, C(CH3)3), 1.34 (s, 9H, C(CH3)3), 0.85 (s, 9H, SiC(CH3)3), 0.55 (s, 3H, SiCH3), 0.54 (s, 3H, SiCH3); 
13C NMR (101 MHz, CDCl3) δ 179.0, 177.5, 167.2, 149.4, 140.1, 129.8, 129.2, 126.0, 122.2, 118.8, 
116.9, 115.0, 58.6, 52.9, 52.7, 51.6, 41.9, 41.8, 26.3, 26.3, 26.1, 19.4, -4.1 ppm (one carbonyl and one 
SiCH3 carbon signals are not resolved); 
IR (film) ?̃? 2960 (w), 2933 (w), 2859 (w), 1763 (m), 1684 (m), 1440 (w), 1366 (w), 1319 (w), 1260 (m), 
1202 (m), 1155 (s), 1006 (w), 969 (w), 842 (w); 
HRMS (ESI) calcd. For C32H46ClN3NaO7Si+ [M+Na]+ 670.2686; found 670.2698. 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-chloro-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7c) 
 
S31 
 
Following general procedure F, 1-(tert-butyldimethylsilyl)-6-chloro-1H-indole (6c) (26.6 mg, 0.100 
mmol, 1 equiv) and cyclopropane 2 were stirred at -50 °C for 44 hours. Preparative TLC using eluent 
9:1 toluene:ethyl acetate afforded dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-chloro-1H-indol-3-yl)-2-
oxo-1,3-dipivaloylimidazolidin-4-yl)malonate (7c) (49.6 mg, 77.0 µmol, 77% yield) as a white solid. 
Chiral HPLC conditions: er = 95.7:4.3; Chiralpak IA 99:1 Hexane/iPrOH, 1.0 mL/min, 31 min. tr (minor) 
= 7.4 min. and tr (major) = 9.7 min. λ = 260 cm-1. 
 
Rf: (SiO2, toluene:ethyl acetate 9:1) 0.5; 
Mp: 126.3-128.8 °C; 
[α]D20.0 = -21.0 (c = 0.30. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 8.6 Hz, 1H, ArH), 7.41 (d, J = 1.7 Hz, 1H, ArH), 7.12 (dd, 
J = 8.5, 1.8 Hz, 1H, ArH), 6.97 (s, 1H, ArH), 5.87 (s, 1H, indole-CH), 4.74 (dd, J = 4.6, 1.1 Hz, 1H, 
indole-CH-CH), 4.13 (d, J = 4.6 Hz, 1H, CH(CO2Me)2), 3.75 (s, 3H, CO2CH3), 3.75 (s, 3H, CO2CH3), 
1.42 (s, 9H, C(CH3)3), 1.35 (s, 9H, C(CH3)3), 0.87 (s, 9H, SiC(CH3)3), 0.55 (s, 3H, SiCH3), 0.54 (s, 3H, 
SiCH3); 
13C NMR (101 MHz, CDCl3) δ 179.0, 177.5, 167.2, 167.2, 149.5, 142.1, 128.6, 128.0, 126.8, 120.8, 
120.1, 117.4, 113.9, 58.6, 52.9, 52.8, 52.7, 51.5, 41.8, 41.8, 26.3, 26.1, 19.3, -4.1 (one aliphatic and one 
SiCH3 carbon signals are not resolved); 
IR (film) ?̃? 2952 (w), 2866 (w), 1762 (m), 1688 (w), 1436 (w), 1331 (w), 1263 (m), 1207 (w), 1158 (s), 
973 (w), 850 (w), 757 (w); 
HRMS (ESI) calcd. For C32H46ClN3NaO7Si+ [M+Na]+ 670.2686; found 670.2684. 
Dimethyl 2-(5-(6-bromo-1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7d) 
 
Following general procedure F, 6-bromo-1-(tert-butyldimethylsilyl)-1H-indole (6d) (31.0 mg, 0.100 
mmol, 1 equiv) and cyclopropane 2 were stirred at -50 °C for 42 hours. Preparative TLC using eluent 
9:1 toluene:ethyl acetate afforded dimethyl 2-(5-(6-bromo-1-(tert-butyldimethylsilyl)-1H-indol-2-yl)-2-
oxo-1,3-dipivaloylimidazolidin-4-yl)malonate (7d) (58.0 mg, 84.0 µmol, 84% yield) as a white solid. 
Chiral HPLC conditions: er = 95.2:4.8; Chiralpak IA 98:2 Hexane/iPrOH, 1.0 mL/min, 31 min. tr (minor) 
= 6.0 min. and tr (major) = 7.3 min. λ = 260 cm-1. 
 
Rf: (SiO2, toluene:ethyl acetate 9:1) 0.51; 
Mp: 71.2-71.9 °C; 
[α]D20.0 = -13.1 (c = 0.3. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 8.4 Hz, 1H, ArH), 7.60 (s, 1H, ArH), 7.29 (s, 1H, ArH), 6.99 
(s, 1H, ArH), 5.89 (s, 1H, indole-CH), 4.76 (d, J = 4.4 Hz, 1H, indole-CH-CH), 4.16 (d, J = 4.3 Hz, 1H, 
CH(CO2Me)2), 3.77 (s, 6H, 2 x CO2CH3), 1.44 (s, 9H, C(CH3)3), 1.37 (s, 9H, C(CH3)3), 0.90 (s, 9H, 
SiC(CH3)3), 0.58 (s, 3H, SiCH3), 0.57 (s, 3H, SiCH3); 
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13C NMR (101 MHz, CDCl3) δ 179.0, 177.5, 167.2, 167.2, 149.5, 142.6, 128.6, 127.1, 123.4, 120.5, 
117.5, 116.9, 115.7, 58.6, 52.9, 52.8, 52.7, 51.5, 41.9, 41.8, 26.3, 26.1, 19.3, -4.0 (one aliphatic and one 
SiCH3 carbon signals are not resolved); 
IR (film) ?̃? 2958 (w), 2866 (w), 1760 (m), 1686 (w), 1459 (w), 1435 (w), 1367 (w), 1330 (w), 1263 (m), 
1213 (w), 1152 (s), 1005 (w), 974 (w), 845 (w), 759 (w); 
HRMS (ESI) calcd. For C32H4679BrN3NaO7Si+ [M+Na]+ 714.2181; found 714.2179. 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-5-fluoro-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7e) 
 
Following general procedure F, 1-(tert-butyldimethylsilyl)-5-methyl-1H-indole (6e) (24.9 mg, 0.100 
mmol, 1 equiv) and cyclopropane 2 were stirred at -50 °C for 42 hours. Preparative TLC using eluent 
9:1 toluene:ethyl acetate afforded dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-5-fluoro-1H-indol-3-yl)-2-
oxo-1,3-dipivaloylimidazolidin-4-yl)malonate (7e) (45.8 mg, 72.0 µmol, 72% yield) as a colorless oil. 
Chiral HPLC conditions: er = 96:4; Chiralpak IA 99:1 Hexane/iPrOH, 1.0 mL/min, 31 min. tr (minor) = 
8.1 min. and tr (major) = 9.2 min. λ = 280 cm-1. 
 
Rf: (SiO2, toluene:ethyl acetate 9:1) 0.58; 
[α]D20.0 = -20.3 (c = 0.30. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.48 (dd, J = 9.8, 2.6 Hz, 1H, ArH), 7.35 (dd, J = 9.0, 4.3 Hz, 1H, ArH), 
7.02 (s, 1H, ArH), 6.90 (td, J = 9.0, 2.6 Hz, 1H, ArH), 5.84 (s, 1H, indole-CH), 4.74 (dd, J = 4.7, 1.1 
Hz, 1H, indole-CH-CH), 4.13 (d, J = 4.6 Hz, 1H, CH(CO2Me)2), 3.77 (s, 3H, CO2CH3), 3.75 (s, 3H, 
CO2CH3), 1.42 (s, 9H, C(CH3)3), 1.35 (s, 9H, C(CH3)3), 0.85 (s, 9H, SiC(CH3)3), 0.54 (s, 3H, SiCH3), 
0.53 (s, 3H, SiCH3); 
13C NMR (101 MHz, CDCl3) δ 179.0, 177.4, 167.2, 167.2, 157.9 (d, J = 235.9 Hz), 149.4, 138.2, 129.7, 
128.6 (d, J = 9.9 Hz), 117.3 (d, J = 4.8 Hz), 114.5 (d, J = 9.7 Hz), 110.2 (d, J = 26.0 Hz), 104.4 (d, J = 
24.2 Hz), 58.6, 52.8, 52.7, 51.5, 41.8, 41.7, 26.3, 26.1, 19.4, -4.1 (one aliphatic and one SiCH3 carbon 
signals are not resolved);  
19F NMR (376 MHz, CDCl3) δ -123.7; 
IR (film) ?̃? 2953 (w), 2867 (w), 1763 (m), 1689 (w), 1479 (w), 1442 (w), 1368 (w), 1318 (w), 1263 (m), 
1214 (m), 1158 (s), 1010 (w), 911 (w), 844 (w), 757 (w); 
HRMS (ESI) calcd. For C32H46FN3NaO7Si+ [M+Na]+ 654.2981; found 654.2986. 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-5-iodo-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7f) 
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Following general procedure F, 1-(tert-butyldimethylsilyl)-5-iodo-1H-indole (6f) (35.7 mg, 0.100 mmol, 
1 equiv) and cyclopropane 2 were stirred at -50 °C for 42 hours. Preparative TLC using eluent 9:1 
toluene:ethyl acetate afforded dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-5-iodo-1H-indol-3-yl)-2-oxo-
1,3-dipivaloylimidazolidin-4-yl)malonate (7f) (57.4 mg, 78.0 µmol, 78% yield) as a white solid. Chiral 
HPLC conditions: er = 96.7:3.3; Chiralpak IA 99:1 Hexane/iPrOH, 1.0 mL/min, 31 min. tr (minor) = 7.1 
min. and tr (major) = 10.1 min. λ = 260 cm-1. 
 
Rf: (SiO2, toluene:ethyl acetate 9:1) 0.58; 
Mp: 71.0-71.5 °C; 
[α]D20.0 = -31.2 (c = 0.30. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 1.7 Hz, 1H, ArH), 7.39 (dd, J = 8.7, 1.7 Hz, 1H, ArH), 7.22 
(d, J = 8.8 Hz, 1H, ArH), 7.00 (s, 1H, ArH), 5.83 (d, J = 1.1 Hz, 1H, indole-CH), 4.73 (dd, J = 4.5, 1.2 
Hz, 1H, indole-CH-CH), 4.17 (d, J = 4.4 Hz, 1H, CH(CO2Me)2), 3.78 (s, 3H, CO2CH3), 3.75 (s, 3H, 
CO2CH3), 1.45 (s, 9H, C(CH3)3), 1.34 (s, 9H, C(CH3)3), 0.85 (s, 9H, SiC(CH3)3), 0.55 (s, 3H, SiCH3), 
0.54 (s, 3H, SiCH3); 
13C NMR (101 MHz, CDCl3) δ 179.0, 177.5, 167.1, 149.4, 140.8, 130.5, 130.2, 129.4, 128.0, 116.5, 
116.0, 83.9, 58.6, 52.9, 52.8, 52.6, 51.6, 41.9, 41.8, 26.4, 26.3, 26.1, 19.4, -4.1 (one SiCH3 signal is not 
resolved); 
IR (film) ?̃? 2955 (w), 2936 (w), 2862 (w), 1765 (m), 1684 (w), 1444 (w), 1364 (w), 1327 (w), 1259 (m), 
1210 (m), 1154 (s), 846 (w), 809 (w), 759 (m); 
HRMS (ESI) calcd. For C32H46IN3NaO7Si+ [M+Na]+ 762.2042; found 762.2048. 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-(methoxycarbonyl)-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7g) 
 
Following general procedure F, methyl 1-(tert-butyldimethylsilyl)-1H-indole-6-carboxylate (6g) (28.9 
mg, 0.100 mmol, 1 equiv) and cyclopropane 2 were stirred at -30 °C for 42 hours. Preparative TLC 
using eluent 65:35 heptane:ethyl acetate afforded dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-
(methoxycarbonyl)-1H-indol-3-yl)-2-oxo-1,3-dipivaloylimidazolidin-4-yl)malonate (7g) (49.2 mg, 
73.0 µmol, 73% yield) as a white solid. Chiral HPLC conditions: er = 95.1:4.9; Chiralpak IA 99:1 
Hexane/iPrOH, 1.0 mL/min, 31 min. tr (minor) = 12.3 min. and tr (major) = 14.8 min. λ = 260 cm-1. 
 
Rf: (SiO2, pentane:ethyl acetate 8:2) 0.5; 
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Mp: 61.7-63.9 °C; 
[α]D20.0 = -9.1 (c = 0.35. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 8.21 (s, 1H, ArH), 7.82 (dd, J = 8.4, 1.3 Hz, 1H, ArH), 7.76 (d, J = 8.5 
Hz, 1H, ArH), 7.18 (s, 1H, ArH), 5.90 (s, 1H, indole-CH), 4.76 (dd, J = 4.5, 1.2 Hz, 1H, indole-CH-
CH), 4.15 (d, J = 4.5 Hz, 1H, CH(CO2Me)2), 3.92 (s, 3H, CO2CH3), 3.75 (s, 3H, CO2CH3), 3.75 (s, 3H, 
CO2CH3), 1.43 (s, 9H, C(CH3)3), 1.34 (s, 9H, C(CH3)3), 0.88 (s, 9H, SiC(CH3)3), 0.60 (s, 3H, SiCH3), 
0.59 (s, 3H, SiCH3); 
13C NMR (101 MHz, CDCl3) δ 179.0, 177.6, 168.0, 167.2, 167.2, 149.5, 141.1, 131.7, 131.7, 123.6, 
121.2, 118.8, 117.6, 116.3, 58.6, 52.9, 52.8, 52.7, 52.0, 51.5, 41.9, 41.8, 26.3, 26.3, 26.1, 19.3, -4.0 (one 
SiCH3 carbon signal not resolved); 
IR (film) ?̃? 2955 (w), 2930 (w), 2861 (w), 1760 (m), 1685 (w), 1442 (w), 1355 (w), 1293 (w), 1262 (m), 
1162 (s), 1001 (w), 839 (w), 758 (w); 
HRMS (ESI) calcd. For C34H49N3NaO9Si+ [M+Na]+ 694.3130; found 694.3141. 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-5-(methoxycarbonyl)-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7h) 
 
Following general procedure F, methyl 1-(tert-butyldimethylsilyl)-1H-indole-5-carboxylate (6g) (35.7 
mg, 0.100 mmol, 1 equiv) and cyclopropane 2 were stirred at -40 °C for 47 hours. Preparative TLC 
using eluent 65:35 heptane:ethyl acetate afforded dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-5-
(methoxycarbonyl)-1H-indol-2-yl)-2-oxo-1,3-dipivaloylimidazolidin-4-yl)malonate (7g) (43.0 mg, 
64.0 µmol, 64% yield) as a colorless oil. Chiral HPLC conditions: er = 92.8:7.2; Chiralpak IA 98:2 
Hexane/iPrOH, 1.0 mL/min, 31 min. tr (minor) = 10.4 min. and tr (major) = 14.9 min. λ = 280 cm-1. 
 
Rf: (SiO2, pentane:ethyl acetate 8:2) 0.5; 
[α]D20.0 = -25.9 (c = 0.25. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 8.45 (d, J = 1.8 Hz, 1H, ArH), 7.86 (dd, J = 8.8, 1.7 Hz, 1H, ArH), 7.46 
(d, J = 8.8 Hz, 1H, ArH), 7.11 (s, 1H, ArH), 5.92 (s, 1H, indole-CH), 4.78 (dd, J = 4.4, 1.3 Hz, 1H, 
indole-CH-CH), 4.18 (d, J = 4.5 Hz, 1H, CH(CO2Me)2), 3.90 (s, 3H, CO2CH3), 3.79 (s, 3H, CO2CH3), 
3.76 (s, 3H, CO2CH3), 1.44 (s, 9H, C(CH3)3), 1.34 (s, 9H, C(CH3)3), 0.87 (s, 9H, SiC(CH3)3), 0.58 (s, 
3H, SiCH3), 0.57 (s, 3H, SiCH3); 
13C NMR (101 MHz, CDCl3) δ 179.0, 177.5, 167.8, 167.2, 167.1, 149.4, 144.4, 129.9, 127.7, 123.3, 
122.1, 121.8, 118.3, 113.7, 58.6, 52.8, 52.7, 51.7, 51.7, 41.8, 41.8, 26.3, 26.1, 19.4, -4.1 (one aliphatic 
and one SiCH3 carbon signals are not resolved); 
IR (film) ?̃? 2959 (w), 2861 (w), 1757 (m), 1689 (m), 1436 (w), 1332 (m), 1264 (s), 1208 (m), 1159 (s), 
968 (w), 844 (w), 814 (w), 758 (m); 
HRMS (ESI) calcd. For C34H49N3NaO9Si+ [M+Na]+ 694.3130; found 694.3140. 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-(trifluoromethyl)-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7i) 
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Following general procedure F, 1-(tert-butyldimethylsilyl)-6-(trifluoromethyl)-1H-indole (6i) (29.9 mg, 
0.100 mmol, 1 equiv) and cyclopropane 2 were stirred at -30 °C for 42 hours. Preparative TLC using 
eluent 9:1 toluene:ethyl acetate afforded dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-(trifluoromethyl)-
1H-indol-2-yl)-2-oxo-1,3-dipivaloylimidazolidin-4-yl)malonate (7i) (56.0 mg, 82.0 µmol, 82% yield) 
as a white solid. Chiral HPLC conditions: er = 95:5; Chiralpak IA 99:1 Hexane/iPrOH, 1.0 mL/min, 31 
min. tr (minor) = 7.2 min. and tr (major) = 8.8 min. λ = 260 cm-1. 
 
Rf: (SiO2, pentane:ethyl acetate 8:2) 0.6; 
Mp: 151.5-152.4 °C; 
[α]D20.0 = -36.7 (c = 0.10. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.90 (d, J = 8.4 Hz, 1H, ArH), 7.71 (s, 1H, ArH), 7.39 (dd, J = 8.5, 1.4 
Hz, 1H, ArH), 7.15 (s, 1H, ArH), 5.92 (s, 1H, indole-CH), 4.75 (dd, J = 4.5, 1.1 Hz, 1H, indole-CH-
CH), 4.15 (d, J = 4.5 Hz, 1H, CH(CO2Me)2), 3.76 (s, 3H, CO2CH3), 3.76 (s, 3H, CO2CH3), 1.43 (s, 9H, 
C(CH3)3), 1.35 (s, 9H, C(CH3)3), 0.88 (s, 9H, SiC(CH3)3), 0.59 (s, 3H, SiCH3), 0.58 (s, 3H, SiCH3); 
13C NMR (101 MHz, CDCl3) δ 179.0, 177.5, 167.2, 167.2, 149.4, 140.6, 130.7, 130.5, 125.1 (q, J = 
271.6 Hz), 124.0 (q, J = 31.7 Hz), 119.7, 117.7, 116.9 (q, J = 3.6 Hz), 111.3 (q, J = 4.2 Hz), 58.6, 52.9, 
52.8, 52.6, 51.4, 41.8, 41.7, 26.3, 26.2, 26.0, 19.3, -4.1 (one SiCH3 carbon is not resolved);  
19F NMR (376 MHz, CDCl3) δ -60.8; 
IR (film) ?̃? 2953 (w), 2935 (w), 2867 (w), 1763 (m), 1689 (w), 1442 (w), 1337 (m), 1263 (m), 1208 (w), 
1158 (s), 1121 (w), 980 (w), 838 (w), 758 (w); 
HRMS (ESI) calcd. For C33H46F3N3NaO7Si+ [M+Na]+ 704.2949; found 704.2966. 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-methyl-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7j) 
 
Following general procedure F, 1-(tert-butyldimethylsilyl)-6-methyl-1H-indole (6j) (24.5 mg, 0.100 
mmol, 1 equiv) and cyclopropane 2 were stirred at -50 °C for 44 hours. Preparative TLC using eluent 
9:1 toluene:ethyl acetate afforded dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-methyl-1H-indol-2-yl)-
2-oxo-1,3-dipivaloylimidazolidin-4-yl)malonate (7j) (51.2 mg, 82.0 µmol, 82% yield) as a white solid. 
Chiral HPLC conditions: er = 90.7:9.3; Chiralpak IA 99:1 Hexane/iPrOH, 1.0 mL/min, 31 min. tr (minor) 
= 6.7 min. and tr (major) = 9.1 min. λ = 260 cm-1. 
 
Rf: (SiO2, toluene:ethyl acetate 9:1) 0.5; 
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Mp: 65.2-67.0 °C; 
[α]D20.0 = -12.4 (c = 0.29. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 8.1 Hz, 1H, ArH), 7.23 (s, 1H, ArH), 6.97 (d, J = 8.2 Hz, 
1H, ArH), 6.94 (s, 1H, ArH), 5.86 (s, 1H, indole-CH), 4.78 (dd, J = 4.6, 1.2 Hz, 1H, indole-CH-CH), 
4.14 (d, J = 4.6 Hz, 1H, CH(CO2Me)2), 3.74 (s, 6H, 2 x CO2CH3), 2.43 (s, 3H, CH3), 1.42 (s, 9H, 
C(CH3)3), 1.34 (s, 9H, C(CH3)3), 0.87 (s, 9H, SiC(CH3)3), 0.55 (s, 3H, SiCH3), 0.53 (s, 3H, SiCH3); 
13C NMR (101 MHz, CDCl3) δ 179.0, 177.5, 167.2, 167.2, 149.6, 142.2, 131.5, 127.7, 126.0, 121.8, 
118.8, 116.9, 114.1, 58.7, 53.0, 52.8, 52.8, 51.7, 41.8, 41.8, 26.3, 26.2, 22.0, 19.4, -3.9, -4.0; 
IR (film) ?̃? 2959 (w), 2928 (w), 2860 (w), 1762 (m), 1738 (m), 1682 (m), 1442 (w), 1362 (w), 1331 (m), 
1257(m), 1207 (m), 1152 (s), 1010 (w), 844 (w), 807 (m), 757 (m); 
HRMS (ESI) calcd. For C33H49N3NaO7Si+ [M+Na]+ 650.3232; found 650.3234. 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-5-methyl-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7k) 
 
Following general procedure F, 1-(tert-butyldimethylsilyl)-5-methyl-1H-indole (6k) (24.5 mg, 0.100 
mmol, 1 equiv) and cyclopropane 2 were stirred at -50 °C for 42 hours. Preparative TLC using eluent 
9:1 toluene:ethyl acetate afforded dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-5-methyl-1H-indol-2-yl)-
2-oxo-1,3-dipivaloylimidazolidin-4-yl)malonate (7k) (48.2 mg, 77.0 µmol, 77% yield) as a white solid. 
Chiral HPLC conditions: er = 95:5; Chiralpak IA 99:1 Hexane/iPrOH, 1.0 mL/min, 31 min. tr (minor) = 
7.2 min. and tr (major) = 8.8 min. λ = 260 cm-1. 
 
Rf: (SiO2, toluene:ethyl acetate 9:1) 0.58; 
Mp: 68.5-69.7 °C; 
[α]D20.0 = -18.1 (c = 0.21. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.46 (s, 1H, ArH), 7.34 (d, J = 8.4 Hz, 1H, ArH), 7.01 (s, 1H, ArH), 6.97 
(d, J = 8.5 Hz, 1H, ArH), 5.86 (s, 1H, indole-CH), 4.79 (d, J = 4.5 Hz, 1H, indole-CH-CH), 4.16 (d, J = 
3.9 Hz, 1H, CH(CO2Me)2), 3.75 (s, 6H, 2 x CO2CH3), 2.42 (s, 3H, CH3), 1.44 (s, 9H, C(CH3)3), 1.34 (s, 
9H, C(CH3)3), 0.87 (s, 9H, C(CH3)3), 0.55 (s, 3H, SiCH3), 0.54 (s, 3H, SiCH3); 
13C NMR (101 MHz, CDCl3) δ 178.9, 177.5, 167.2, 167.1, 149.6, 140.0, 129.2, 128.8, 128.3, 123.3, 
118.8, 116.5, 113.7, 58.7, 53.0, 52.8, 52.7, 51.7, 41.8, 41.8, 26.3, 26.3, 26.2, 21.4, 19.4, -4.1 (one SiCH3 
carbon signal is not resolved); 
IR (film) ?̃? 2954 (w), 2861 (w), 1764 (m), 1689 (w), 1466 (w), 1367 (w), 1262 (w), 1156 (s), 1001 (w), 
840 (w), 791 (w), 760 (w); 
HRMS (ESI) calcd. For C33H49N3NaO7Si+ [M+Na]+ 650.3232; found 650.3232. 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-methoxy-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7l) 
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Following general procedure F, 1-(tert-butyldimethylsilyl)-6-methoxy-1H-indole 6l (26.1 mg, 0.100 
mmol, 1 equiv) and cyclopropane 2 were stirred at -50 °C for 48 hours. Preparative TLC using eluent 
9:1 toluene:ethyl acetate, followed by a second preparative TLC using eluent 92:8 toluene:ethyl acetate 
afforded dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-methoxy-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate 7l (41.2 mg, 64.0 µmol, 64% yield) as a white solid. Chiral HPLC 
conditions: er = 93.4:6.6; Chiralpak IA 99:1 Hexane/iPrOH, 1.0 mL/min, 31 min. tr (minor) = 9.1 min. 
and tr (major) = 13.0 min. λ = 260 cm-1. 
 
Rf: (SiO2, toluene:ethyl acetate 9:1) 0.54; 
Mp: 71.4-71.7 °C; 
[α]D20.0 = -22.3 (c = 0.24. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 8.8 Hz, 1H, ArH), 6.95 (d, J = 2.2 Hz, 1H, ArH), 6.87 (s, 
1H, ArH), 6.82 (dd, J = 8.7, 2.2 Hz, 1H, ArH), 5.85 (t, J = 0.8 Hz, 1H, indole-CH), 4.77 (dd, J = 4.7, 
1.1 Hz, 1H, indole-CH-CH), 4.12 (d, J = 4.7 Hz, 1H, CH(CO2Me)2), 3.82 (s, 3H, OCH3), 3.75 (s, 3H, 
CO2CH3), 3.75 (s, 3H, CO2CH3), 1.41 (s, 9H, C(CH3)3), 1.35 (s, 9H, C(CH3)3), 0.88 (s, 9H, SiC(CH3)3), 
0.54 (s, 3H, SiCH3), 0.53 (s, 3H, SiCH3); 
13C NMR (101 MHz, CDCl3) δ 179.0, 177.5, 167.2, 167.2, 156.1, 149.6, 142.6, 126.8, 122.7, 119.7, 
117.1, 109.1, 98.6, 58.7, 55.7, 53.0, 52.8, 52.8, 51.6, 41.8, 41.8, 26.3, 26.2, 19.5, -4.1, -4.1 (one aliphatic 
carbon signal is not resolved); 
IR (film) ?̃? 2959 (w), 2860 (w), 1756 (m), 1737 (w), 1682 (w), 1621 (w), 1559 (w), 1442 (w), 1325 (w), 
1257 (m), 1207(m), 1152 (m), 1035 (w), 985 (w), 844 (w), 801 (w), 757 (m); 
HRMS (ESI) calcd. For C33H49N3NaO8Si+ [M+Na]+ 666.3181; found 666.3182. 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-phenyl-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7m) 
 
Following general procedure F, 1-(tert-butyldimethylsilyl)-6-phenyl-1H-indole (6m) (30.8 mg, 0.100 
mmol, 1 equiv) and cyclopropane 2 were stirred at -50 °C for 48 hours. Preparative TLC using eluent 
9:1 toluene:ethyl acetate afforded dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-phenyl-1H-indol-2-yl)-
2-oxo-1,3-dipivaloylimidazolidin-4-yl)malonate (7m) (51.7 mg, 75.0 µmol, 75% yield) as a white solid. 
Chiral HPLC conditions: er = 92.3:7.7; Chiralpak IB 99:1 Hexane/iPrOH, 1.0 mL/min, 31 min. tr (minor) 
= 8.1 min. and tr (major) = 9.3 min. λ = 280 cm-1. 
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Rf: (SiO2, toluene:ethyl acetate 9:1) 0.57; 
Mp: 155.0-156.2 °C; 
[α]D20.0 = -9.3 (c = 0.30. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 8.3 Hz, 1H, ArH), 7.65 (s, 1H, ArH), 7.59 (d, J = 7.2 Hz, 
2H, ArH), 7.44 (t, J = 7.7 Hz, 2H, ArH), 7.40 (dd, J = 8.3, 1.5 Hz, 1H, ArH), 7.32 (t, J = 7.4 Hz, 1H, 
ArH), 7.04 (s, 1H, ArH), 5.92 (s, 1H, indole-CH), 4.81 (dd, J = 4.6, 1.2 Hz, 1H, indole-CH-CH), 4.16 
(d, J = 4.6 Hz, 1H, CH(CO2Me)2), 3.77 (s, 3H, CO2CH3), 3.76 (s, 3H, CO2CH3), 1.44 (s, 9H, C(CH3)3), 
1.36 (s, 9H, C(CH3)3), 0.91 (s, 9H, SiC(CH3)3), 0.59 (s, 3H, CH3), 0.58 (s, 3H, CH3); 
13C NMR (101 MHz, CDCl3) δ 179.0, 177.5, 167.2, 149.6, 142.5, 142.3, 135.4, 128.8, 128.7, 127.5, 
127.3, 126.6, 120.0, 119.4, 117.2, 112.7, 58.7, 52.9, 52.8, 52.8, 51.6, 41.8, 41.8, 26.3, 26.2, 19.4, -4.0 
(one carbonyl, one aliphatic and one SiCH3 carbon signals are not resolved); 
IR (film) ?̃? 2954 (w), 2861 (w), 1758 (m), 1690 (m), 1468 (w), 1431 (w), 1333 (w), 1258 (m), 1203 (m), 
1154 (s), 975 (w), 839 (w), 759 (w); 
HRMS (ESI) calcd. For C38H51N3NaO7Si+ [M+Na]+ 712.3388; found 712.3390. 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-1,6,7,8-tetrahydrocyclopenta[g]indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7n) 
 
Following general procedure F, 1-(tert-butyldimethylsilyl)-1,6,7,8-tetrahydrocyclopenta[g]indole (6n) 
(28.9 mg, 0.100 mmol, 1 equiv) and cyclopropane 2 were stirred at -50 °C for 42 hours. Preparative 
TLC using eluent 9:1 toluene:ethyl acetate afforded dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-1,6,7,8-
tetrahydrocyclopenta[g]indol-3-yl)-2-oxo-1,3-dipivaloylimidazolidin-4-yl)malonate (7n) (39.4 mg, 
60.0 µmol, 60% yield) as a white solid. Chiral HPLC conditions: er = 90.5:9.5; Chiralpak IA 98:2 
Hexane/iPrOH, 1.0 mL/min, 31 min. tr (minor) = 5.7 min. and tr (major) = 7.3 min. λ = 280 cm-1. 
 
Rf: (SiO2, toluene:ethyl acetate 9:1) 0.51; 
Mp: 70.7-71.1 °C; 
[α]D20.0 = -11.7 (c = 0.20. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 8.0 Hz, 1H, ArH), 7.12 (d, J = 8.0 Hz, 1H, ArH), 7.05 (s, 
1H, ArH), 5.87 (s, 1H, indole-CH), 4.78 (dd, J = 4.5, 1.2 Hz, 1H, indole-CH-CH), 4.13 (d, J = 4.5 Hz, 
1H, CH(CO2Me)2), 3.75 (s, 3H, CO2CH3), 3.75 (s, 3H, CO2CH3), 3.13 (t, J = 7.2 Hz, 2H, CH2CH2CH2), 
2.99 (t, J = 7.3 Hz, 2H, CH2CH2CH2), 2.10 (p, J = 7.3 Hz, 2H, CH2CH2CH2), 1.43 (s, 9H, C(CH3)3), 
1.35 (s, 9H, C(CH3)3), 0.84 (s, 9H, SiC(CH3)3), 0.58 (s, 3H, SiCH3), 0.56 (s, 3H, SiCH3); 
13C NMR (101 MHz, CDCl3) δ 178.9, 177.3, 167.2, 167.1, 149.6, 139.7, 139.4, 129.1, 128.0, 127.1, 
117.6, 117.3, 117.2, 58.6, 52.9, 52.8, 52.7, 51.8, 41.8, 41.7, 34.5, 33.2, 26.5, 26.3, 25.9, 19.6, -1.1, -1.1; 
IR (film) ?̃? 2958 (w), 2860 (w), 1761 (w), 1687 (w), 1472 (w), 1435 (w), 1319 (w), 1257 (m), 1208 (m), 
1153 (s), 1036 (w), 846 (w), 809 (w), 754 (w); 
HRMS (ESI) calcd. For C35H51N3NaO7Si+ [M+Na]+ 676.3388; found 676.3400. 
Dimethyl 2-(2-oxo-1,3-dipivaloyl-5-(1-(triisopropylsilyl)-1H-pyrrol-3-yl)imidazolidin-4-
yl)malonate (7o) 
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Following general procedure F, 1-(triisopropylsilyl)-1H-pyrrole (6o) (22.3 mg, 0.100 mmol, 1 equiv) 
and cyclopropane 2 were stirred at -30 °C for 42 hours. Preparative TLC using eluent 65:35 
heptane:ethyl acetate afforded dimethyl 2-(2-oxo-1,3-dipivaloyl-5-(1-(triisopropylsilyl)-1H-pyrrol-3-
yl)imidazolidin-4-yl)malonate (7o) (42.1 mg, 69.0 µmol, 69% yield) as a colorless oil. Chiral HPLC 
conditions: er = 88.8:11.2; Chiralpak IF 99:1 Hexane/iPrOH, 1.0 mL/min, 31 min. tr (minor) = 14.2 min. 
and tr (major) = 15.3 min. λ = 260 cm-1. 
 
Rf: (SiO2, pentane:ethyl acetate 8:2) 0.44; 
[α]D20.0 = -5.3 (c = 0.21. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 6.66 (t, J = 2.5 Hz, 1H, ArH), 6.61 (s, 1H, ArH), 6.21 (dd, J = 2.8, 1.5 
Hz, 1H, ArH), 5.55 (s, 1H, pyrrol-CH), 4.76 (dd, J = 4.8, 1.1 Hz, 1H, pyrrol-CH-CH), 4.08 (d, J = 4.8 
Hz, 1H, CH(CO2Me)2), 3.74 (s, 3H, CO2CH3), 3.70 (s, 3H, CO2CH3), 1.40-1.32 (m, 21H, 2 x C(CH3)3 
+ 3 x SiCH), 1.07-1.01 (m, 18H, CH(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 179.4, 177.5, 167.3, 167.2, 149.4, 125.0, 124.9, 121.0, 108.1, 59.6, 53.5, 
52.7, 52.7, 51.7, 41.8, 41.7, 26.4, 26.3, 17.8, 11.6; 
IR (film) ?̃? 2952 (w), 2869 (w), 1755 (m), 1736 (m), 1682 (m), 1464 (w), 1436 (w), 1354 (w), 1315 (w), 
1260 (m), 1206 (m), 1152 (s), 1099 (m), 1011 (w), 856 (w), 749 (w), 691 (w); 
HRMS (ESI) calcd. For C31H51N3NaO7Si+ [M+Na]+ 628.3388; found 628.3396. 
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6. Derivatizations of the products 
Dimethyl 2-(5-(6-bromo-1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-2-oxo-1-pivaloylimidazolidin-
4-yl)malonate (12) 
 
In a microwave vial, a solution of dimethyl 2-(5-(6-bromo-1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-
2-oxo-1,3-dipivaloylimidazolidin-4-yl)malonate (7d) (111 mg, 0.160 mmol, 1 equiv) in 2.8 mL of 
isopropanol was added, followed by hydrazine (80% wt in water, 14.6 µL, 0.240 mmol, 1.5 equiv) and 
stirred for 20 minutes. Then, 1 mL of a 1 M HCl aqueous solution was added, followed by 2 mL of 
water. The aqueous phase was extracted with 3x5 mL of dichloromethane, dried over Na2SO4, filtered 
and evaporated, to afford dimethyl 2-(5-(6-bromo-1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-2-oxo-1-
pivaloylimidazolidin-4-yl)malonate (12) (92.0 mg, 0.151 mmol, 94% yield) as a white solid. Chiral 
HPLC conditions: er = 95.8:4.2; Chiralpak IA 90:10 Hexane/iPrOH, 1.0 mL/min, 31 min. tr (major) = 
12.3 min. and tr (minor) = 15.3 min. λ = 260 cm-1. 
 
Rf: (SiO2, pentane:ethyl acetate 2:1) 0.52; 
Mp: 68.8 °C (degradation); 
[α]D20.0 = 25.7 (c =0.15. CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 1.8 Hz, 1H, ArH), 7.51 (d, J = 8.5 Hz, 1H, ArH), 7.23 (dd, 
J = 8.5, 1.7 Hz, 1H, ArH), 7.06 (s, 1H, ArH), 5.69 (s, 1H, NH), 5.63 (d, J = 3.0 Hz, 1H, indole-CH), 
4.16 (ddd, J = 7.5, 3.1, 1.4 Hz, 1H, indole-CH-CH), 3.78 (s, 3H, CO2CH3), 3.71 (s, 3H, CO2CH3), 3.67 
(d, J = 7.4 Hz, 1H, CH(CO2CH3)2), 1.28 (s, 9H, C(CH3)3), 0.88 (s, 9H, SiC(CH3)3), 0.58 (s, 3H, SiCH3), 
0.57 (s, 3H, SiCH3). 
13C NMR (101 MHz, CDCl3) δ 178.3, 167.2, 167.0, 154.1, 142.5, 129.7, 126.9, 123.4, 119.9, 117.1, 
116.9, 115.5, 56.1, 55.7, 55.0, 53.2, 53.0, 41.5, 26.4, 26.1, 19.3, -4.0, -4.0. 
IR (film) ?̃? 3291 (w), 2955 (w), 2931 (w), 2860 (w), 1734 (s), 1675 (w), 1460 (w), 1434 (w), 1286 (w), 
1194 (m), 1152 (m), 973 (w), 838 (w), 805 (w), 756 (w); 
HRMS (ESI) calcd. For C27H3979BrN3O6Si+ [M+H]+ 608.1786; found 608.1789. 
Methyl 2-(5-(6-bromo-1H-indol-3-yl)-2-oxoimidazolidin-4-yl)acetate (13) 
 
i) dimethyl 2-(5-(6-bromo-1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-2-oxo-1-pivaloylimidazolidin-4-
yl)malonate (12) (64.0 mg, 0.105 mmol, 1 equiv) was dissolved in 0.7 mL of tetrahydrofuran in a 
microwave vial, and a 0.5 M aqueous solution of LiOH (1.7 mL, 0.84 mmol, 8 equiv) was added, and 
the mixture stirred for 13 hours at room temperature. The reaction was acidified to pH 1 using a 1 M 
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aqueous HCl solution. The aqueous layer was extracted with 3x3 mL of ethyl acetate. The combined 
organic layers were washed with 7 mL of 1 M aqueous NaOH solution. The aqueous layer was extracted 
with 5 mL of ethyl acetate, and then acidified to pH 1 using 1 M aqueous HCl solution, and finally 
extracted with 3x10 mL of ethyl acetate. The combined organic layers were dried over Na2SO4, filtered 
and concentrated to afford crude product. 
ii) The crude product was dissolved in 2.1 mL of methanol, and heated to 80 °C for 16 hours, then cooled 
to rt. 
iii) The solution was cooled to 0 °C, and a 2 M solution of TMSdiazomethane in diethyl ether (0.53 mL, 
1.1 mmol, 10 equiv) was added until gas evolution ceased. The solution was then evaporated and 
subjected to column chromatography (SiO2, eluent dichloromethane:methanol 100:0 to 98:2 to 95:5) to 
afford methyl 2-(5-(6-bromo-1H-indol-3-yl)-2-oxoimidazolidin-4-yl)acetate (13) (20.9 mg, 59.0 µmol, 
56% yield over three steps) as a pale brown solid. Chiral HPLC conditions: er = 96.3:3.7; Chiralpak IC 
50:50 Hexane/iPrOH, 1.0 mL/min, 31 min. tr (major) = 9.7 min. and tr (minor) = 13.4 min. λ = 210 cm-
1. 
 
Rf: (SiO2, dichloromethane:methanol 9:1) 0.28; 
Mp: 87.0 - 88.9 °C; 
[α]D20.0 = 97.4 (c = 0.24. MeOH); 
1H NMR (400 MHz, CD3OD) δ 7.60 (d, J = 8.5 Hz, 1H, ArH), 7.54 (d, J = 1.7 Hz, 1H, ArH), 7.27 (s, 
1H, ArH), 7.15 (dd, J = 8.5, 1.8 Hz, 1H, ArH), 4.76 (d, J = 6.5 Hz, 1H, Indole-CH), 4.15 – 4.06 (m, 1H, 
indole-CH-CH), 3.63 (s, 3H, CH3) 2.73 – 2.63 (m, 2H). 
13C NMR (101 MHz, CD3OD) δ 172.9, 165.2, 139.6, 125.6, 125.1, 123.3, 121.5, 116.3, 116.1, 115.5, 
58.3, 56.9, 52.2, 40.4. 
IR (film) ?̃? 3249 (w), 2952 (w), 2924 (w), 2854 (w), 1691 (s), 1614 (w), 1546 (w), 1440 (w), 1360 (w), 
1332 (w), 1213 (w), 1176 (w), 1106 (w), 1050 (w), 896 (w), 804 (w), 759 (w); 
HRMS (ESI) calcd. For C14H1579BrN3O3+ [M+H]+ 352.0291; found 352.0292.  
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7.Crystal structure of 7d 
 
Figure S1. Crystal structure of 7d. 
A single crystal was grown by slow evaporation of the solution of 7d in Methanol. Supplementary 
crystallographic data for this compound have been deposited at Cambridge Crystallographic Data Centre 
(1815214) and can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif. 
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8. Spectra of new compounds 
Dimethyl 3-oxo-2,4-dipivaloyl-2,4-diazabicyclo[3.1.0]hexane-6,6-dicarboxylate (2) 
1H-NMR (400 MHz, CDCl3) 
  
13C-NMR (101 MHz, CDCl3)
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IR 
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1-(Tert-butyldimethylsilyl)-5-chloro-1H-indole (6b) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
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IR 
 
  
S47 
 
1-(Tert-butyldimethylsilyl)-6-chloro-1H-indole (6c) 
1H-NMR (400 MHz, CDCl3)
 
13C-NMR (101 MHz, CDCl3) 
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IR 
 
  
S49 
 
1-(tert-butyldimethylsilyl)-6-methyl-1H-indole (6j) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
 
 
 
S50 
 
IR 
 
  
S51 
 
1-(tert-butyldimethylsilyl)-6-phenyl-1H-indole (6m) 
1H-NMR (400 MHz, CDCl3)
 
13C-NMR (101 MHz, CDCl3)
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IR 
 
  
S53 
 
1-(tert-butyldimethylsilyl)-1,6,7,8-tetrahydrocyclopenta[g]indole (6n) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
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IR 
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Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-2-oxo-1,3-dipivaloylimidazolidin-4-
yl)malonate (7a) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
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HPLC 
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IR 
 
  
S58 
 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-5-chloro-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7b) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
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HPLC 
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IR 
 
  
S61 
 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-chloro-1H-indol-3-yl)-2-oxo-1,3-dipivaloylimidazolidin-
4-yl)malonate (7c) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
 
 
 
S62 
 
HPLC 
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IR 
 
  
S64 
 
Dimethyl 2-(5-(6-bromo-1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-2-oxo-1,3-dipivaloylimidazolidin-
4-yl)malonate (7d) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
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HPLC 
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IR 
 
  
S67 
 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-5-fluoro-1H-indol-3-yl)-2-oxo-1,3-dipivaloylimidazolidin-
4-yl)malonate (7e) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
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19F NMR (376 MHz, CDCl3) 
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HPLC 
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IR 
 
  
S71 
 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-5-iodo-1H-indol-3-yl)-2-oxo-1,3-dipivaloylimidazolidin-4-
yl)malonate (7f) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
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HPLC 
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IR 
 
  
S74 
 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-(methoxycarbonyl)-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7g) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
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HPLC 
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IR 
 
  
S77 
 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-5-(methoxycarbonyl)-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7h) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
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HPLC 
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IR 
 
  
S80 
 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-(trifluoromethyl)-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7i) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
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19F NMR (376 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S82 
 
HPLC 
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IR 
 
  
S84 
 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-methyl-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7j) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
 
 
S85 
 
HPLC 
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IR 
 
  
S87 
 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-5-methyl-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7k) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
 
 
S88 
 
HPLC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S89 
 
IR 
 
  
S90 
 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-methoxy-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7l) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
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HPLC 
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IR 
 
  
S93 
 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-6-phenyl-1H-indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7m) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
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HPLC 
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IR 
 
  
S96 
 
Dimethyl 2-(5-(1-(tert-butyldimethylsilyl)-1,6,7,8-tetrahydrocyclopenta[g]indol-3-yl)-2-oxo-1,3-
dipivaloylimidazolidin-4-yl)malonate (7n) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
 
 
S97 
 
HPLC 
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IR 
 
  
S99 
 
Dimethyl 2-(2-oxo-1,3-dipivaloyl-5-(1-(triisopropylsilyl)-1H-pyrrol-3-yl)imidazolidin-4-
yl)malonate (7o) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
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HPLC 
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IR 
 
  
S102 
 
(4S,4'S)-dimethyl 2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4-carboxylate) (9) 
1H-NMR (400 MHz, CDCl3)  
 
13C-NMR (101 MHz, CDCl3) 
 
 
 
S103 
 
IR 
 
  
S104 
 
((4S,4'S)-2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(diphenylmethanol) (10a) 
1H-NMR (400 MHz, CDCl3)  
 
13C-NMR (101 MHz, CDCl3)
 
 
 
S105 
 
IR 
 
  
S106 
 
((4S,4'S)-2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(di-m-tolylmethanol) (10b) 
1H-NMR (400 MHz, CDCl3)  
 
13C-NMR (101 MHz, CDCl3) 
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IR 
 
  
S108 
 
((4S,4'S)-2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(di-p-tolylmethanol) (10c) 
1H-NMR (400 MHz, CDCl3)  
13C-NMR (101 MHz, CDCl3) 
 
S109 
 
IR 
 
  
S110 
 
((4S,4'S)-2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(bis(3,5-
dimethylphenyl)methanol) (10d) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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IR 
 
  
S112 
 
((4S,4'S)-2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(bis(3,5-di-tert-
butylphenyl)methanol) (10e) 
1H-NMR (400 MHz, CDCl3)  
 
13C-NMR (101 MHz, CDCl3) 
 
S113 
 
IR 
 
  
S114 
 
((4S,4'S)-2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(bis(3,5-
dimethoxyphenyl)methanol) (10f) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
S115 
 
IR 
 
  
S116 
 
((4S,4'S)-2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(bis(3,5-
bis(trifluoromethyl)phenyl)methanol) (10g) 
1H-NMR (400 MHz, CDCl3)  
 
13C-NMR (101 MHz, CDCl3) 
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19F NMR (376 MHz, CDCl3) 
 
IR 
 
  
S118 
 
((4S,4'S)-2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole-4,2-diyl))bis(di(naphthalen-2-
yl)methanol) (10h) 
1H-NMR (400 MHz, CDCl3)  
 
13C-NMR (101 MHz, CDCl3) 
 
S119 
 
IR 
 
S120 
 
(4S,4'S)-2,2'-(propane-2,2-diyl)bis(4-((benzyloxy)diphenylmethyl)-4,5-dihydrooxazole) (11a) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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IR 
 
  
S122 
 
Dimethyl 2-(5-(6-bromo-1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-2-oxo-1-pivaloylimidazolidin-
4-yl)malonate (12) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
S123 
 
HPLC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S124 
 
IR 
 
  
S125 
 
Methyl 2-(5-(6-bromo-1H-indol-3-yl)-2-oxoimidazolidin-4-yl)acetate (13) 
1H-NMR (400 MHz, CD3OD) 
 
13C-NMR (101 MHz, CD3OD) 
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HPLC 
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IR 
 
  
S128 
 
1,1'-(2-oxo-1H-imidazole-1,3(2H)-diyl)bis(2,2-dimethylpropan-1-one) (18) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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IR 
 
  
S130 
 
Dimethyl 2,4-diacetyl-3-oxo-2,4-diazabicyclo[3.1.0]hexane-6,6-dicarboxylate (19) 
1H-NMR (400 MHz, CDCl3)  
 
13C-NMR (101 MHz, CDCl3) 
 
S131 
 
IR 
 
  
S132 
 
Dimethyl 2,4-dibenzoyl-3-oxo-2,4-diazabicyclo[3.1.0]hexane-6,6-dicarboxylate (20) 
1H-NMR (400 MHz, CDCl3)  
 
13C-NMR (101 MHz, CDCl3) 
 
S133 
 
IR 
 
  
S134 
 
(2S,2'S)-dimethyl 2,2'-((2,2-dimethylmalonyl)bis(azanediyl))bis(3-hydroxypropanoate) (35) 
1H-NMR (400 MHz, CDCl3)  
 
13C-NMR (101 MHz, CDCl3) 
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IR 
 
  
S136 
 
Dimethyl 2-(1,3-dibenzoyl-5-(1H-indol-3-yl)-2-oxoimidazolidin-4-yl)malonate (37a) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
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HPLC 
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IR 
 
  
S139 
 
Dimethyl 2-(1,3-dibenzoyl-5-(1-methyl-1H-indol-3-yl)-2-oxoimidazolidin-4-yl)malonate (37b) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
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HPLC 
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IR 
 
  
S142 
 
Dimethyl 2-(1,3-dibenzoyl-5-(1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-2-oxoimidazolidin-4-
yl)malonate (37c) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
 
 
S143 
 
HPLC 
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IR 
 
  
S145 
 
Dimethyl 2-(1,3-diacetyl-5-(1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-2-oxoimidazolidin-4-
yl)malonate (38) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
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HPLC 
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IR 
 
